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ABSTRACT 
THE RELATIONSHIP BETWEEN BODY MASS INDEX AND BREAST CANCER 
RECURRENCE/PROGRESSION AND BREAST CANCER-SPECIFIC DEATH 
Cedomir Tosevski 
Master of Science 
Faculty of Applied Health Sciences 
Brock University 
2010 
The aim of this study was to describe the nonlinear association between body mass index 
(BMI) and breast cancer outcomes and to determine whether BMI improves prediction of 
outcomes. A cohort of906 breast cancer patients diagnosed at Henry Ford Health 
System, Detroit (1985-1990) were studied. The median follow-up was 10 years. 
Multivariate logistic regression was used to model breast cancer recurrence/progression 
and breast cancer-specific death. Restricted cubic splines were used to model nonlinear 
effects. Receiver operator characteristic areas under the curves (ROC AUC) were used to 
evaluate prediction. BMI was nonlinearly associated with recurrence/progression and 
death (p= 0.0230 and 0.0101). Probability of outcomes increased with increase or 
decrease ofBMI away from 25. BMI splines were suggestive of improved prediction of 
death. The ROC AUCs for nested models with and without BMI were 0.8424 and 0.8331 
(p= 0.08). If causally associated, modifying patients BMI towards 25 may improve 
outcomes. 
XVI 
CHAPTER 1: INTRODUCTION 
1.1 The Impact of Breast Cancer among Canadian Women 
On average, 445 Canadian women will be diagnosed with breast cancer and 100 
Canadian women will die of breast cancer every week. Canadian women have a 1 in 9 
lifetime cumulative risk of developing breast cancer and a 1 in 28 chance of dying from 
breast cancer-specific death (based on life tables standardized to the Canadian census 
population from 1991 up to 85 years of age ).1 These estimates are representative of an 
age-standardized incidence rate of 102 per 100,000, the highest among all cancers, as 
well as, an age-standardized mortality rate of 21 per 100,000, second only to lung cancer. 
Figures 1 and 2 display trends in cancer incidence and mortality over the past 30 years. 1 
Much of the long-term increase in incidence may be attributed to the increased 
prevalence of mammography screening and increased utilization of popUlation based 
screening programs. Additionally, changes in reproductive patterns such as delayed 
childbearing and having fewer children, the rising prevalence rate of obesity and 
postmenopausal hormone use (i.e. hormone replacement therapy (HRT)) may have 
contributed to the increase in breast cancer incidence. Meanwhile, reduced breast cancer 
mortality rates have been attributed to improvements in treatment and mammography 
screening (detecting those women diagnosed with breast cancer at an earlier stage of 
disease).2,3 
In Ontario women, according to Canadian Cancer Statistics 2010, breast cancer is 
the most frequently diagnosed cancer, followed by colorectal cancer and lung cancer. 1 
Lung cancer is the leading cause of cancer death, followed by breast cancer and 
1 
colorectal cancer.! In 2010, an estimated 8,900 women will be diagnosed with breast 
cancer and approximately 2,100 women will die of breast cancer. 1 
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Figure 1. Age-Standardized Incidence Rates for Selected Cancers, Females, Canada, 
1981-2010.1 
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Figure 2. Age-Standardized Mortality Rates for Selected Cancers, Females, Canada, 
1981-2010.1 
2 
1.2 Why Study Obesity and Breast Cancer Outcomes? 
In the last decade the prevalence of obesity has nearly doubled. This increase in 
prevalence is evident in the US and Canada, with the highest prevalence of obesity 
reported in the US .4-6 Studies show that body mass index (BMI) is a risk factor for breast 
cancer, as well as, a prognostic factor for breast cancer recurrence/progression and 
overall surviva1. The risk of breast cancer is modified by menopausal status and is 
therefore different in postmenopausal and premenopausal women.7 Generally, 
postmenopausal women with a high BMI are at an increased risk of breast cancer 
whereas premenopausal women with a high BMI are at a lower risk of developing breast 
cancer. Studies evaluating the prognostic relationship between BMI and breast cancer 
outcomes show that women with a high BMI at breast cancer diagnosis have shorter 
overall survival and a higher risk of breast cancer recurrence/progression.4, 8-10 
1.3 Gaps in the Literature 
Although past studies evaluated the relationship between BMI and breast cancer 
outcomes, results have been inconsistent and limited. Major emphasis was placed on the 
role of high BMI and literature failed to simultaneously assess the impact oflow BMI on 
breast cancer outcomes. In addition, several investigations focused on all cause mortality, 
which would hide relationships specific to breast cancer death. Recent literature has 
analyzed BMI but only in broad categorical groups or as linear effects. Greenberg and 
colleagues, Katoh and colleagues, Menon and colleagues and Carmichael and colleagues 
modeled BMI in broad categorical groups and as a result did not find a significant 
association between BMI and breast cancer recurrence and overall surviva1. II -14 Katoh 
and colleagues used a BMI > 27 kg/m2 vs. a BMI of < 27 kg/m2 whereas Greenberg and 
3 
colleagues used a BM! of> 27 kg/m2 vs. a BM! of < 20 kg/m2 to define high and low 
BM!. II, 12 Modeling BM! in broad categorical groups may have accounted for the null 
findings demonstrated by these authors. Finally, studies have yet to assess prediction 
using sophisticated statistical techniques such as bootstrapping for internal validation and 
assessment of discrimination and calibration, leaving a large gap in knowledge. 
1.4 Response to Gaps in the Literature 
In order to address the gaps in the literature the following research questions are 
addressed: 
(1) Determine whether BMI near or at breast cancer diagnosis is independently associated 
with breast cancer recurrence/progression and breast cancer-specific death, after covariate 
adjustment? 
(2) Evaluate whether BMI is nonlinearly associated with breast cancer 
recurrence/progression and breast cancer-specific death? 
(3) Determine whether properly modeled BMI improves the ability to predict breast 
cancer recurrence/progression and breast cancer-specific death? 
In this study, BMI was modeled using restricted cubic splines. Restricted cubic 
splines are higher ordered polynomials used in exploring complicated nonlinear 
relationships. They are versatile and can fit highly curving shapes. To determine whether 
BMI was independently associated with breast cancer outcomes, BMI was adjusted for 
well-established covariates, which were chosen a priori and from past studies, such as 
age, stage, estrogen receptor/progesterone receptor hormone (ERlPR) status, surgery, 
radiation therapy and chemotherapy. To determine whether BMI improves the ability to 
predict breast cancer outcomes, prediction was evaluated using bootstrapping for internal 
4 
validation and by assessing discrimination and calibration. Bootstrapping estimates the 
sampling distribution of an estimator by resampling with replacement from the original 
sample. IS Discrimination measures the models ability to separate those women who will 
experience a breast cancer recurrence/progression or die from breast cancer from those 
who will not by calculating the proportion of pairs of women in which the woman with 
breast cancer recurrence/progression or breast cancer-specific death has a higher 
predicted risk than the woman without breast cancer recurrence/progression or breast 
cancer-specific death. IS Finally, calibration assesses how well the predicted probabilities 
match the observed probabilities. IS, 16 
1.5 Conclusions 
This study is important for a multiplicity of reasons. The purpose of the association study 
was to determine if BMI near or at breast cancer diagnosis was associated with breast 
cancer recurrence/progression and breast cancer-specific death. Considering that BMI 
and breast cancer outcomes are related, this study would allow further investigation into 
possible etiologic or causal mechanisms. In addition, the results of this study may aid in 
the formulation of intervention programs such as nutritional and exercise training 
programs for women diagnosed with breast cancer as these programs may be beneficial 
to the patient (and the health care system at large). On the other hand,prediction models 
are used in clinical settings by physicians and health policy makers in order to generate 
predictions regarding the probability/risk of a patient surviving breast cancer. Therefore, 
models predicting breast cancer outcomes need to be able to discriminate correctly, while 
at the same time be able to optimize calibration and goodness-of-fit. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.0 Overview 
The current chapter provides the rationale and basis for this study. The chapter begins 
with an overview of the biology and etiology of breast cancer. Then, age-standardized 
incidence and mortality rates are briefly reported for the US and Canada. Provided is a 
discussion of the breast cancer risk factors, pertinent prognostic factors, as well as, the 
role of breast cancer prognostic models in clinical and public health settings. The chapter 
ends with a focus on body mass index (BMI) as a relevant prognostic factor for breast 
cancer recurrence/progression and breast cancer-specific death. Particular attention is 
given to modeling BMI using restricted cubic splines and its nonlinear association with 
breast cancer outcomes. 
2.1 Defining Cancer 
Cancer is a term used for diseases in which abnormal cells uncontrollably mutate, grow 
and proliferate within the body. 17 All cancers are initiated within cells. Under normal 
conditions, cells grow and divide in a controlled manner in order to produce additional 
cells, as cells are required for bodily functions. Eventually, these cells become old or 
damaged and as a result these cells die and are replaced with new cells. However, this 
process can sometimes be disrupted. The genetic material of a cell can become damaged 
or altered, resulting in alterations in DNA base-pair sequences which affect normal cell 
growth and division. As a result, cells are alive when they should be dead but because 
they are damaged or mutated, they do not function normally and new cells start to form 
when the body does not require these extra cells. Therefore, these excess cells are capable 
of forming a mass or tissue referred to as a tumor. 17 
6 
2.1.1 Breast Cancer Categories 
Cancer is a complex disease that encompasses multiple disease categories. The five main 
. . I d 17 categorIes mc u e: 
(l) Carcinoma: Cancer that begins in epithelial cells or cells lining the 
mesodermal origin. In addition, carcinomas have the ability to invade 
surrounding tissues and organs and metastasize to lymph nodes or other sites. 
(2) Sarcoma: Cancer that is initiated in bone, cartilage, fat, muscle, blood vessels 
and other connective or supportive tissues of mesodermal origin. 
(3) Leukemia: Cancer that initiates in blood-forming tissue such as bone marrow 
and causes large numbers of abnormal blood cells to be produced and to enter 
the blood. 
(4) Lymphoma and myeloma: Cancers that start in the cells of the immune 
system. 
(5) Central nervous system cancers: Cancers arising in the tissues of the brain 
and spinal cord. 
Nearly all breast cancers are classified as carcinomas because the cancer begins 
within the epithelial cells of the breast. 
Breast tissue is made up of glands for the production of milk (lobules) and the 
ducts that connect the lobules to the nipple (Figure 3). The remainder of the breast is 
composed of fatty, connective and lymphatic tissues. 18 
7 
2.2 Types of Breast Cancer 
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Figure 3. The Breast. 19 
Two types of masses affect breast tissue: benign or invasive/infiltrating. Benign masses 
are not cancerous, they do not uncontrollably grow or spread and are therefore not life 
threatening. In contrast to benign masses, majority of breast cancers are potentially 
invasive. These tumors are deemed cancerous and have the ability to metastasize or 
spread from the lobules or ducts of the breast into surrounding tissue or regional lymph 
nodes or distant tissues or lymph nodes. 17, 18 
2.2.1 Ductal and Lobular Carcinoma in Situ (DCIS and LCIS) 
nCIS is the most common type of non-invasive breast cancer. nCls and LCIS are termed 
in situ because the cancer is confined to either the ducts or lobules. 18 DCIS is only 
evident in the ducts of the breast because it does not spread through the basement 
membrane of the epithelium and into surrounding breast tissue. On the other hand, LCIS 
8 
is initiated in the lobules and does not penetrate the lobular walls. nCls is the most 
common type of non-invasive breast cancer. 18, 20 
2.2.2 Invasive/Infiltrating Ductal and Lobular Carcinoma (IDC and ILC) 
IDC is initiated within the ducts of the breast. The cancer eventually spreads through the 
basement membrane of the epithelium and invades the breast tissue. Once the cancer 
penetrates the basement membrane of the epithelium it is able to metastasize to other 
parts of the body. IDC accounts for 8 out oflO invasive breast cancers.19 On the other 
hand, ILC penetrates through the lobular epithelium's basement membrane and then can 
metastasize to other parts of the body. Approximately, lout of 10 breast cancers are 
classified as ILC. 19 
2.2.3 Inflammatory Breast Cancer (IBC) 
IBC is characterized as rapidly developing « 3 months) signs and symptoms of diffuse 
erythema, peau d'orange (orange skin) and increasing size of the breast(s) with or without 
evidence of extensive dermal lymphatic invasion on core biopsy specimens.8, 19 IBC is a 
rare type of breast cancer that can grow and metastasize suddenly, even at an early 
stage?I,22 IBC is likely to develop when breast cancer cells block the lymph vessels 
which are responsible for removing fluids, bacteria and waste products from the breast 
tissue resulting in inflammation of the breast.2! IBC accounts for 1-3% of breast cancers 
diagnosed in the US. 19 Women diagnosed with IBC have a lower overall survival and an 
increased risk of breast cancer-specific death.22 
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2.3 Breast Cancer Staging 
2.3.1 Brief History 
In 1904, Steinthal, a German physician, proposed the division of breast cancer into three 
distinct stages: (1) Stage 1- small tumors that were localized to the breast, (2) Stage II-
large tumors involving axillary lymph nodes, and (3) Stage III- tumors that invaded tissue 
around the breast. Later, Steinthal's staging system was refined by Greenough, who 
based his classification on microscopic evaluation of breast cancer specimens. 
Following Greenough's revision, the tumor-node-metastasis (TNM) classification 
system for breast cancer staging was developed by Pierre Denoix beginning in 1942.23 
The TNM principal objective, as displayed in Table 1, was to classify cancer based on 
major morphological attributes of malignant tumors that were thought to influence 
disease prognosis such as size and extension of the primary tumor (T), presence and 
extent of regional lymph node involvement (N) and presence of distant metastases (M). 
In 1977, the American Joint Committee on Cancer (AJCC) published their first breast 
cancer staging system report, which was based on the TNM staging system. Following, in 
1985, the International Union Against Cancer presented a clinical classification for breast 
cancer based on the TNM classification system.23 
2.3.2 Overview of the TNM Staging Principles 
The TNM staging system encompasses four different classifications: clinical (cTNM), 
pathologic (PTNM), recurrence (rTNM) and autopsy (aTNM)?3 
cTNM: Is utilized in order to make local/regional treatment recommendations. It 
is solely based on evidence gathered prior to initial treatment of the primary tumor: 
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Physical examination, imaging studies (such as mammography and ultrasound) and 
pathologic examination of the breast or other tissues obtained from biopsy.23 
Furthermore, additional descriptors when identifying special cases of cTNM and 
pTNM classification include: The "m" prefix in cases with multiple tumors and the "y" 
prefix in cases where classification is performed during or following initial multimodality 
therapy (for example, neoadjuvant chemotherapy, radiation therapy or both).23 
pTNM: Pathology is used to assess the extent of disease and to make 
recommendations for treatment. It incorporates results of clinical staging with additional 
evidence obtained from surgery and pathologic examinations of the primary tumor, 
lymph nodes and primary metastases (only if metastases occurred).23 
rTNM: Is utilized when additional treatment is required for a tumor that has 
recurred after a disease-free period.23 
aTNM: Is used for cancers discovered after the death of a patient.23 
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Table 1. TNM Classification for Breast Cancer from the AJCC Cancer Staging 
Manual, 6th Edition 
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2.3.3 Histopathologic Grading 
Aside from stage, histopathologic grading is associated with overall and metastasis free 
survival (defined from the date of curative treatment to the date of diagnosis of distant 
metastasis). Also, histopathologic grading is helpful for choosing the appropriate therapy. 
Knowledge of the tumor grade avoids under treatment of high grade tumors (grade 3) and 
over treatment of low grade tumors (grade 1). In comparing high and low grade tumors, 
high grade tumors are consideredaggressive.24 To date, the Scarff-Bloom-Richardson 
(SBR) tumor grading system has been the most widely accepted and utilized tumor 
grading system in clinical settings. The SBR tumor grading system examines three grade 
features: (1) Ductoglandular formation (percentage of cancer composed of tubular 
structures), (2) Nuclear pleomorphism (change in cell size and uniformity), and (3) 
Mitosis count (rate of cell division). In calculating the histopathologic grade score, each 
above mentioned feature is assigned a score between 1-3 (1 indicating more normal 
histologic or cellular appearance or slower cell growth and 3 indicating more abnormal 
histologic or cellular appearance or faster cell growth).24 Then, the score of each feature 
is added together for a final score that ranges from 3-9. A tumor with a final score of 3,4 
or 5 is considered a grade 1 tumor. A sum of 6 or 7 is considered a grade 2 tumor and a 
sum of 8 or 9 is considered a grade 3 tumor. 
2.4 Epidemiology of Breast Cancer 
2.4.1 Incidence and Mortality Trends: An International Perspective 
According to the American Cancer Society report on Global Cancer Facts & Figures 
2007, breast cancer is the most frequently diagnosed cancer in women. Age-standardized 
breast cancer incidence rates vary internationally, with the highest number of cases 
13 
reported in North America, Australia and Northern and Western Europe. In contrast, 
Eastern Europe reported intermediate levels whereas large parts of Africa and Asia 
reported the lowest levels. In 2002, breast cancer incidence rates varied internationally by 
more than 25-fold.25 In developing countries the variation in incidence was attributed to 
low screening rates, lack of cancer registries or incomplete reporting of breast cancers. 
Age-standardized breast cancer incidence rates ranged from 3.9 per 100,000 in 
Mozambique to 101.1 per 100,000 in the US. In 2007, approximately 1.3 million new 
cases of invasive breast cancer and an estimated 465,000 breast cancer deaths were 
predicted to occur world-wide.25 
Over the past 25 years the incidence rate for breast cancer increased by 30% in 
developed countries, resulting from a shift in reproductive patterns and an increase in 
screening adoption.25,26 Additionally, the increase in prevalence of obesity has been 
associated with an increase in postmenopausal breast cancer risk.26 Also, since 1981 there 
has been controversy regarding the role of hormones on breast cancer development. It has 
been noted that current use of oral contraceptives modestly increases the risk of breast 
cancer. Furthermore, postmenopausal hormone replacement therapy (HRT) increases 
breast cancer risk (the risk is exacerbated with prolonged use).3, 26 
On the other hand, breast cancer mortality rates over the past 25 years have been 
leveling off or decreasing in most developed countries. As depicted in Figure 4, mortality 
rates in the United Kingdom, Canada and Australia have been decreasing, possibly 
resulting from improvements in treatment and an increase in mammography screening.25 
On the other hand, trends in mortality rates have not been favourable in Poland and 
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Japan. It has been speculated that dietary exposure specifically, high fat diets are 
responsible for the increase in breast cancer incidence and subsequently death.27 
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Figure 4. Trends in Age-Standardized Death Rates of Breast Cancer in Five 
Countries.25 
2.4.2 Incidence and Mortality Trends in US Women 
Breast cancer accounts for approximately 1 in 4 cancers diagnosed among US women.3 
According to the Breast Cancer Facts & Figures 2009-2010 report put forth by the 
American Cancer Society, breast cancer incidence tends to increase with age. During the 
period of 2002-2006 women between the ages of 20-24 reported the lowest incidence rate 
(1.4 per 100,000) whereas women aged 75-79 reported the highestincidence rate (441.9 
per 100,000).3 However, breast cancer incidence after 80 years of age decreased possibly 
due to a reduction in screening. 3 
Race. As depicted in Figure 5, White women tend to have a higher breast cancer 
incidence rate beginning at age 45 years. On the other hand, Blacks are at higher risk 
before the age of 45 years and are more likely to die from breast cancer at every age.3 
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Figure 5. Female Breast Cancer- Incidence and Mortality Rates by Age and Race, 
US, 2002-2006.3 
Calendar year. Incidence rates have been inconsistent for invasive breast cancer 
during 1975-2006. During 1975-1985, the incidence rate was constant whereas after 1980 
the incidence rate rose by 4.0% annually until 1987. Then, a constant pattern was 
observed during 1987-1994, rising again by 1.6% per year during the period of 1994-
1999. Lastly, during 1999-2006, the incidence rate decreased by 2.0% per year. As 
previously mentioned, changes in reproductive patterns and greater utilization of breast 
cancer screening may have resulted in the increase of breast cancer incidence.3 However, 
the decrease in breast cancer incidence observed more recently may have been a result of 
decreased mammography screening and HRT. 3, 28-30 On the other hand, the incidence rate 
for in situ breast cancer has been increasing during 1980-1990, due to higher utilization 
of mammography screening, as observed in Figure 6.3 
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Figure 6. Incidence Rates of Invasive and In Situ Female Breast Cancer by Age, 
Adjusted for Delayed Reporting, US, 1975-2006.3 
Finally, death from breast cancer has been decreasing since the 1990's.3,30 
Particularly, from 1990-2006, death rates decreased by 3.2% per year among women less 
than 50 years and by 2.0% annually in women 50 years and older.3, 30, 31 
2.4.3 Incidence and Mortality Trends in Canada 
As depicted in Figure 7, during 1980-2004, breast cancer incidence and mortality trends 
have been shifting in Ontario.32 For example, women between the ages of 50-69 years 
experienced an increase in incidence across the 1980's and thereafter incidence continued 
to rise steadily. A similar pattern was observed for women of all ages during 1980-2004. 
The pattern observed in the 1990's resulted from the consistent use of mammography 
screening.32 
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Figure 7. Breast Cancer Incidence and Mortality Rates in Ontario, 1981-2004.32 
Between 1989-2004, death from breast cancer decreased by 33%.32 The decrease 
in breast cancer-specific death was attributed to improvements in treatment and 
screemng. 
In summary, comparable patterns for breast cancer incidence and mortality were 
observed in American and Canadian women, fOf' the most part an increase in incidence 
and a decrease in mortality. Generally in major westernized countries, the incidence has 
been increasing while mortality has leveled off or decreased. 
2.5 Breast Cancer Risk Factors 
Modifiable and non-modifiable breast cancer risk factors playa key. role in breast 
carcinogenesis. Modifiable risk factors are preventable whereas non-modifiable risk 
factors cannot be prevented. Modifiable risk factors include: being overweight or obese 
after menopause, use ofHRT, excess alcohol consumption, physical inactivity and age at 
first full-term pregnancy?' 30 On the other hand, non-modifiable breast cancer risk factors 
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include: age, family history, benign breast disease, inherited genetic mutations in breast 
cancer susceptibility genes BRCAI and BRCA2, early menarche, age at menopause and 
1 b d · d . 1 h l· 3 30 33 34 W menopausa status, reast enslty an atyplca yperp aSia.' " omen 
encompassing any of the aforementioned risk factors are considered to be at higher risk 
for breast cancer. Table 2 outlines the previously mentioned risk factors and additional 
breast cancer risk factors in order of strength of their association. 
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Table 2. Factors that Increase the Relative Risk for Breast Cancer in Women 
(Adapted from Breast Cancer Facts & Figures, 2009-2010)3 
Relative Risk 
>4.0 
2.1-4.0 
1.1-2.0 
Factors that affect Circulating hormones 
Other factors 
Factor 
Female 
Age (65+ vs. <.65 years, although risk increases across all ages until age 80) 
Certain inherited genetic mutations for breast cancer (BRCA1 andlor BRCA2) 
Two or more firs t-degree relatives with breast cancer diagnosed at an early age 
Personal history of breast cancer 
High breast tissue density 
Biopsy-confirmed atypical hyperplasia 
One first-degree relative with breast ca ncer 
High-dose radiation to chest 
High bone density (postmenopausal) 
Late age at first fu ll-term pregnancy (>30 years) 
Early menarche «12 years) 
Late menopause (>55 years) 
No full-term pregnancies 
Never breastfed a child 
Recent oral contraceptive use 
Recent and long-term use of estrogen and progestin 
Obesity (postmenopausa l) 
Personal history of endometrial or ovar ian cancer 
Alcohol consumption 
Height (ta ll) 
High socioeconomic status 
Ashkenazi Jewish heritaqe 
Occupational risk factors: Exposure to toxins and light at night has been under 
investigation and are considered risk factors for breast cancer. Steenland and colleagues 
found that increased exposure to ethylene oxide, a fumigant used to sterilize surgical 
instruments, was shown to cause breast cancer in animals. Also, ethylene oxide was 
associated with higher breast cancer risk among women employed in commercial 
sterilization facilities. 35 Additionally, flight attendants who experience circadian rhythm 
disruption by crossing multiple time zones are at an increased risk for breast cancer.3 
Similar studies conducted on night shift work and exposure to light found concordant 
results. In flight attendants and nurses it was noted that the increase in breast cancer risk 
was a result of low melatonin levels that occur because of exposure to light at night. 3 
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2.5.1 The Role of Menopausal Status and BMI on Breast Cancer Risk 
It is suggested that BMI is inversely related to breast cancer risk among premenopausal 
women whereas postmenopausal women experience a weak to moderate increase in 
breast cancer risk with increasing BM!. 13, 36,37 However, results have been inconsistent. 
Majority of case-control studies found that BMI was positively associated with 
postmenopausal breast cancer whereas cohort studies demonstrated weak or null 
associations.36 
Trentham-Dietz and colleagues used a case-control study to compare incident 
cases of breast cancer to controls in order to determine the relationship between BMI and 
breast cancer risk.7 BMI was reported in quintiles and logistic regression was used to 
adjust for parity, age at first birth, age at menarche, family history of breast cancer, recent 
alcohol consumption, education, and for postmenopausal women, age at menopause. In 
analysis, BMI was weakly associated with decreased risk of premenopausal breast 
cancer. In multivariate logistic regression, for every 1 kg/m2 increase in BMI there was a 
2% decrease in premenopausal breast cancer risk (OR= 0.98; 95% CI= 0.97-1.00;p= 
0.03).7 On the other hand, high BMI was associated with increased risk of 
postmenopausal breast cancer. Moreover, adjusted for the aforementioned covariates, per 
1 kg/m2 increase in BMI there was a 3% increase in postmenopausal breast cancer risk 
(OR= 1.03; 95% CI= 1.02-1.04;p < 0.001).7 
Huang and colleagues prospectively examined BMI at 18 years and at midlife 
along with adult weight change in relation to subsequent risks of premenopausal and 
postmenopausal breast cancer incidence and mortality among a large cohort of US female 
nurses (the Nurse's Health Study cohort). The age-adjusted relative risk (RR) for breast 
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cancer was close to the null for current BMI up to 26 kg/m2 however declined with 
greater adiposity in premenopausal women.36 In contrast, current BMI and breast cancer 
incidence in postmenopausal women was positively associated. However, this association 
was not significant. In addition, stratified analyses by hormone use demonstrated a 
stronger positive association between current BMI and breast cancer risk in those women 
who never used HRT (RR= 1.59; 95% CI= 1.09-2.32;p < 0.001).36 
2.5.2 Etiologic Mechanisms in Obese Premenopausal Breast Cancer Patients 
The difference in premenopausal and postmenopausal breast cancer risk is that obese 
premenopausal women on average have longer, more irregular menstrual cycle lengths 
and a greater tendency for anovulatory cycles.4, 7, 38-41 The increase in anovulation is a 
result of low serum estradiol and progesterone levels on target breast cells and a 
consequent reduced risk of breast cancer.4, 42 
2.5.3 Etiologic Mechanisms in Obese Postmenopausal Breast Cancer Patients 
In postmenopausal women, endogenously produced estrogens playa key role in breast 
cancer risk and mortality.43-45 Estrogens, derived from androgenic steroids in adipose 
tissue, are more likely to increase breast cancer riskin obese postmenopausal women.7-1O, 
36,42,45,46 According to Figure 8,the elevation in estrone is mediated by the 
aromatization, in adipose tissue ofthe C19 steroid androstenedione, which is secreted by 
the adrenal glands and postmenopausal ovaries. As a result, levels of androstenedione and 
aromatase are high in obese postmenopausal women. Then, adipose tissue derived 
estrone is available for conversion to the more biologically potent estradiol. Finally, the 
circulating levels of estrone and estradiol are positively correlated with body weight. 
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Elevation in these estrogens has been associated with increased breast cancer risk in 
obese postmenopausal women. 18,40,47 
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Figure 8. The Metabolic Production of Estrone and Estradiol from the C19 Steroid 
Androstenedione and the Bioavailability of Estradiol in Postmenopausal Women.40 
However, this relationship diminishes in postmenopausal women who take 
exogenous estrogen from HRT.48 HRT masks the aforementioned association because 
exogenous hormones artificially elevate the amount of circulating estrogens to such a 
degree in lean and obese women; that the increase in circulating estrogens in adipose 
tissue is negligible. 
In addition, obese women have lower levels of sex hormone-binding globulin 
(SHBG) which may increase breast cancer risk by raising serum free estradiol and free 
testosterone levels.7, 9, 36, 41, 46, 47, 49, 50 Thus, excess estrogen and testosterone may 
influence both the characteristics and growth rate of the breast tumor. 51 
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McTiernan and colleagues examined the association between adiposity and 
concentrations of androgens, estrogens and SHBG in a population-based, multicenter, 
multi ethnic prospective cohort of 1,185 breast cancer patients.44 Of the 1,185 breast 
cancer survivors, 503 were postmenopausal. Obese women (BMI > 30 kg/m2) had a 35% 
higher concentration of estrone compared to women with a BMI < 22 kg/m2 (p= 0.005).44 
Moreover, estradiol concentrations increased by 130% in obese women when compared 
to their lighter counterparts (p= 0.002).44 Additionally, concentrations oftestosterone 
increased as adiposity increased and as a result, obese women had twice the testosterone 
concentration when compared to their lighter counterparts (p= 0.0001).44 Furthermore, 
free estradiol and testosterone levels were significantly higher in overweight and obese 
women compared to the lightest women (p= 0.0001). Finally, SHBG levels significantly 
decreased with increasing BMI (p= 0.0001).44 
2.5.4 Insulin and Insulin-Like Growth Factors (IGFs), Menopausal Status 
and Breast Cancer Risk in Obese Women 
According to Figure 9, insulin and IGF are found in high levels in obese women and 
have shown to express mitogenic effects on normal and neoplastic breast epithelial cells; 
particularly in premenopausal women because insulin and IGF potentiate the effects of 
. 1· 20 21 41 45 46 H . 1· . d . 1·· dr h Clrcu atmg estrogens. ' , " ypennsu memla an msu m resIstance syn orne ave 
been involved in the mechanisms by which excess weight increases premenopausal breast 
cancer risk. Furthermore, insulin and IGF exert their effect by reducing circulating levels 
of SHBG and as a result increasing circulating estrone and estradiol levels. For example, 
Del Giudice and colleagues demonstrated that elevated plasma insulin concentrations 
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were associated with premenopausal breast cancer risk after adjusting for age and body 
weight. 54 
Figure 9. Obesity and the Interaction between Estradiol and Sex Hormone-Binding 
Globulin (SHBG) and Insulin and Leptin in Breast Cacner Cell Proliferation and 
Angiogenesis.4o 
Also, elevated plasma IGF-Ilevels were associated with an increased risk of 
breast cancer. However, this relationship was only observed in premenopausal women.40 
For example, Li and colleagues extracted total and free plasma IGF-I and IGF-binding 
protein-3 (IGFBP) concentrations in 40 newly diagnosed premenopausal and 
postmenopausal breast cancer patients and 40 race and age matched healthy controls.55 In 
analysis, there was no significant difference in mean BMI between cases and controls. 
Adjusted for menopausal status, free IGF.;.1 but not total IGF-I was significantly 
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associated with an increased breast cancer risk. Also, a highIGF-lIIGFBP-3 ratio was a 
significant risk factor for breast cancer development. 55 
2.5.5 Mechanisms of Leptin and Breast Cancer Risk in Obese Women 
Leptin is a neuroendocrine hormone solely produced in adipose tissue. It is suggested that 
the biological actionsofleptin are associated with obesity and breast cancer development 
and progression.8, 56 Leptin fuels the growth of human breast cancer cell lines in vitro and 
the expression of proteolytic enzymes, which are necessary for breast tissue invasion.4o, 
57-59 
Like insulin, leptin can modify estrogenic activity and therefore, has the ability to 
influence the biological behavior of estrogen-dependent breast cancers. The mechanism 
of action is by way of estrogen production because leptin can induce the activity of 
aromatase (an enzyme responsible for the biosynthesis of estrone from androstenedione 
in adipose tissue ).40,45 Tessitore and colleagues conducted a case-control study and found 
elevated plasma leptin levels and an increase in adipose tissue leptin mRNA levels in 23 
breast cancer patients.6o However, the number of cases and controls were too few to draw 
appropriate conclusions. 
2.6 Breast Cancer Prognosis 
2.6.1 Defining Breast Cancer Mortality and Survival 
Mortality or mortality rate and survival or survival rate are often incorrectly used 
interchangeably. Mortality rate is the number of deaths per population (usually 100,000) 
per unit time whereas survival measures the time it takes to develop an outcome of 
interest. Survival can be measured using Cox proportional hazards regression which uses 
time-to-event survival analysis. Survival analysis examines and models the time it takes 
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for an event to occur. In this study, survival was defined from the time of primary breast 
cancer diagnosis to time of breast cancer-specific death. In studying survival, multiple 
outcomes can be assessed in patients diagnosed with breast cancer. The four distinct 
outcomes are: breast cancer recurrence/progression, breast cancer-specific survival, 
competing-causes survival and all cause or overall survival. 61,62 
1) Breast cancer recurrence/progression: (a) Recurrence. LocaVregional cancer 
recurrence following a curative resection, and (b) Progression. Local spread 
or distant recurrence/metastasis following an attempted cure. 
2) Breast cancer-specific survival: Time from primary breast cancer diagnosis 
to time of breast cancer-specific death. 
3) All cause or overall survival: Time from primary breast cancer diagnosis to 
time of death from any cause. 
4) Competing-causes survival: Time from primary breast cancer diagnosis to 
time of death from any cause other than breast cancer. 
This study will examine breast cancer recurrence/progression and breast cancer-
specific death. 
2.6.2 Five-Year Relative Survival Ratio (RSR): Canadian Population 
Like mortality, survival is also an important indicator of cancer burden. Survival is a 
measure of disease severity. Survival estimates are used to establish priority areas for 
improving cancer prognosis and contro1.63 Population-based survival estimates are 
expressed as ratios. RSR is defined as the ratio of the observed survival for a group of 
people diagnosed with cancer to the survival expected for people of the same general 
I · 64 popu atlOn. 
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Between the period of 2002-2004, the five-year RSR for breast cancer in 
Canadian women was 87% (95% CI= 87-88%). In interpreting the RSR, those women 
diagnosed with breast cancer between 2002-2004 were estimated to be 87% as likely to 
live for another five-years when compared to members of the general population.63 
RSR by province, 2002-2004. The age-standardized breast cancer five-year RSR 
for males and females combined in Canada was 87% (95% CI= 87-88%). For example, 
Ontario (88%; 95% CI= 87-88%) and Alberta (88%; 95% CI= 86-89%) had the highest 
five-year RSR whereas Prince Edward Island (84%; 95% CI= 79-89%) and Nova Scotia 
(84%; 95% CI= 82-86%) reported the lowest five-year RSR rates.63 A possible 
explanation for the difference in the five-year RSR among provinces is that provincial 
regulations for screening and early detection may be different for each province. In 
addition, access to specialized cancer treatment and differences in population 
characteristics may also contribute to the different five-year RSR's observed by province. 
RSR by age, 2002-2004. The five-year RSR for breast cancer was different for all 
age groups. However, the five-'year RSR was lowest among those who were diagnosed at 
a later age. For instance, women diagnosed with breast cancer between the ages of 60-69 
had the highest five-year RSR, 90% (95% CI= 89-90%). On the other hand, persons 
diagnosed between 80-99 years had the lowest five-year RSR, 80% (95% CI= 77_82%).63 
Generally, survival tends to decrease with age because individuals diagnosed with 
cancer receive less therapy due to the presence of comorbidities. The presence of 
comorbidities reduces the body's ability to tolerate and respond to treatment.63 This 
pattern is evident in those women diagnosed with breast cancer as the five-year RSR by 
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age decreased in women between 60-69 years old vs. 80-99 years old, from 90% to 
80%.63 
RSR estimates/or 2002-2004 vs.1992-1994. The five-year RSR for breast cancer 
increased approximately 5% between 1992-1994 and 2002-2004.63 
2.6.3 Five-Year Survival Rates: US Population 
According to Surveillance, Epidemiology, and End Results (SEER), the overall five-year 
relative survival during 1999-2006 from 17 SEER geographic areas was 89.0%. 
Furthermore, the relative five-year survival by race was: 90.2% for White women and 
77.5% for Black women.65 
The relative five-year survival rate by stage at diagnosis for all races combined 
was: 98.0% (localized), 83.6% (regional), 23.4% (distant) and 57.9% (unknown), 
respectively.65 
2.6.4 Covariates Predicting Breast Cancer Survival 
In exploring previous literature, Shek and Godolphin derived a multivariate Cox model 
that incorporated prognostic factors that demonstrated independent predictive value for 
overall surviva1.66 Clinicopathologic variables collected at time of breast cancer diagnosis 
were: stage, based on the TNM staging classification system, axillary node status, ER 
status, age and menopausal status. Stepwise regression was utilized to identify important 
covariates, at a chosen significance level of p ~ 0.05. 
Using stepwise regression, nodal status was the primary variable forced into Cox 
models as it produced the maximum likelihood. Followed by stage (as stage improved the 
likelihood of the preceding variable), demonstrating that individuals who were in a higher 
stage of their disease had more detrimental effects. Then, the negative coefficient of log .. 
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ER was added and was indicative of a reduced risk associated with increasing ER 
concentration. Also, tumor necrosis was associated with lower overall survival when 
compared to minimal or no necrosis.66 All covariates were added in the same manner and 
decision not to include additional covariates to Cox models was based on the above 
mentioned significance level. 
The study conducted by Shek and Godolphin contained strengths and limitations. 
The study had a large sample size (n= 1,184) and a follow-up of 10 years. Also, an 
extensive set of prognostic variables were available for analysis. However, the study did 
possess limitations. A major flaw was the criteria used for prognostic covariate selection. 
Stepwise regression and a significance level of p :'S 0.05 for developing prediction models 
is not a highly regarded technique.67 Instead, using a priori covariate selection alongside 
"backward" elimination, with a level of significance of p :'S 0.2 (however this is not a 
fixed value) for predictor selection is the preferred method because it provides better 
prediction.67 
Newman and colleagues examined whether obesity was related to breast cancer-
specific survival after covariate adjustment. 10 The following variables were tested in 
univariate Cox models and deemed significant predictors of breast cancer-specific 
survival: age (p= 0.03), size of tumor, number of positive nodes, clinical stage, ERIPR 
status (each with p < 0.001), chemotherapy and radiation therapy (p= 0.02).10 
Furthermore, tumor size, number of positive nodes and ER status were highly statistically 
significant in multivariate models adjusted for any clinical and histopathologic predictors. 
Also, adjusted for tumor size, number of positive nodes and ER status; PR status, stage 
and radiation therapy ceased to be statistically significant. Chemotherapy maintained a 
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marginal level of statistical significance. 10 The study conducted by Newman and 
colleagues found concordant results with Shek and Godolphin, that tumor size, node 
positive tumors and low ER status correlates with poor breast cancer-specific survival 
and overall survival. 10, 66 Some studies also found that radiation therapy, HRT and 
tamoxifen were important predictors of overall survival.4, 9, 68 Additional prognostic 
factors associated with breast cancer survival included: race, history of benign breast 
disease, education level, menopausal status, oral contraceptive use, age at menopause, 
protein intake, physical activity and smoking.4, 9, 68 However, there are issues surrounding 
the above mentioned prognostic variables. Many of these prognostic variables are only 
associated with survival in univariate but not multivariate analysis. Also, some of the 
aforementioned prognostic variables are only associated with competing causes survival 
and not breast cancer-specific survival. For this study, well established prognostic factors 
chosen a priori and from past literature will include: age, stage, ERiPR status, surgery, 
radiation therapy and chemotherapy. 10, 66, 69-71 
2.6.5 Mechanisms Underlying Low BMI and Breast Cancer Prognosis 
Moon and colleagues suggest that a mechanistic relationship exists between low BMI and 
poor breast cancer outcomes after treatment. This process involves tumor-modulating 
roles of local and systemic adipocytes. Animal experiments have demonstrated that the 
presence of mammary adipocytes is critical for mammary gland development and 
irradiation of mammary fat pads caused malignant progression of normal mammary 
cells.61 To date, the above mentioned mechanistic relationship is not fully understood and 
future research should further examine this relationship. 
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2.7 Obesity and Breast Cancer Survival 
2.7.1 Obesity and Overall Survival 
Obesity is one prime example of a modifiable risk factor that can be controlled through 
diet and physical activity.3, 72, 73 Even though obesity is a modifiable risk factor, the 
prevalence of obesity in women has nearly doubled during the past decade and the 
increase in prevalence is evident globally, in the US and Canada.4-6, 74 To date, literature 
suggests that women who are overweight or obese at breast cancer diagnosis are found to 
have worse overall and recurrence-free survival. 8 
2.7.2 Measuring Obesity 
Obesity is defined as the buildup of adipose tissue in excess and to an extent that impairs 
both physical and psychosocial health and well-being.75 Even though it is possible to 
measure body fat directly, these methods are expensive, time-consuming and do not 
pertain to fieldwork and clinical practice. Instead, the Quetelet Index (QI) or BMI is used 
as a proxy to measure body fat. BMI is calculated using weight in kilograms (kg) divided 
by height in meters squared (m2).74, 75 BMI is a standardized classification system used to 
compare obesity prevalence rates worldwide. Furthermore, BMI categories are used to 
develop plans for health management and to track changes in the obesity epidemic. A 
widely utilized classification system is the World Health Organization (WHO) 
international classification system of adult underweight, normal, overweight and obesity, 
as outlined in Table 3.5,75-78 
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Table 3. The International Classification System of Adult Underweight, Normal, 
Overweight and Obesity According to BMI 
(Adapted from WHO, 2009)78 
Classification BMI (kg/m~) 
Principal cut-off 
points 
Underweight <18.50 
Severe thinness <16.00 
Moderate thinness 16.00-16.99 
Mild thinness 17.00-18.49 
Normal range 18.50-24.99 
Overweight ~25.00 
Pre-obese 25.00-29.99 
Obese ~30.00 
Obese class I 30.00-34.99 
Obese class II 35.00-39.99 
Obese class III ~40.00 
2.7.3 Using BMI as a Proxy to Measure Body Fat Percent 
Liu and colleagues measured the consistency between BMI and body fat percent in 200 
Taiwanese women diagnosed with breast cancer.79 Body fat and fat-free mass were 
measured by bioelectrical impedance one day before breast surgery and BMI was 
calculated using weight in kilograms (kg) divided by height in meters squared (m2). The 
relationship between BMI and fat/lean mass was tested by Pearson's correlation 
coefficient (r). Furthermore, accuracy was calculated using sensitivity and specificity to 
reflect the diagnostic performance ofBMI in detecting body fat percent defined obesity. 
In analysis, BMI was strongly correlated with fat mass (r= 0.96;p < 0.001) and body fat 
percent (r= 0.91; p < 0.001). In addition, the correlation between BMI and fat-free mass 
was moderate and significant (r= 0.49; p < 0.001). However, BMI demonstrated poor 
sensitivity for identifying obesity (47%; 95% CI= 39-55) and excellent specificity (99%; 
95% CI= 92_100).79 This study contained limitations such as a small sample size and 
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differences in ethnic variation. The study sample was limited to Asians thus results were 
not externally generalizable as different BMI cut-points may need to be utilized for 
different races. For instance, in defining obesity using BMI in Black women there is a 
potentially confounding influence because of their high bone mineral density and skeletal 
muscle mass; resulting in an elevated BMI. In order for BMI to be an accurate measure of 
adiposity, BMI requires that body weight is a true depiction of adiposity and that adult 
height is not influenced by extraneous pathologic conditions. Despite BMl's limitation as 
a surrogate measure of body fat, to date, BMI is considered convenient and simple in 
clinical practice and research. 
2.7.4 Obesity and Breast Cancer Recurrence/Progression 
Loi and colleagues examined the effect of obesity on distant recurrence in newly 
diagnosed breast cancer patients. Time to failure was considered from the date of breast 
cancer diagnosis. Date of distant recurrence (abstracted from medical records) was used 
as the time of failure. Women who were not known to have had a distant recurrence but 
died were assumed to have failed at the date of death. In analysis, 1,101 cases were used 
for time to distant recurrence. so Eight hundred-thirteen women were premenopausal and 
288 women were postmenopausaL During follow-up, 264 distant recurrences were 
observed. In unadjusted analysis, obesity (BMI > 30 kg/m2) was associated with an 
increased risk of distant recurrence from breast cancer (HR= 1.50; 95% CI= 1.07-2.09; 
p= 0.02) .80 Also, age, tumor grade, nodal status and PR hormone positive status were 
found to independently predict distant recurrence. Since majority of patients were 
premenopausal, estrogen levels influenced by peripheral aromatization in adipose tissue 
is insignificant compared with that produced by functioning ovaries. Additionally, in 
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obese premenopausal women, the hormonal make-up is different and obesity has been 
associated with unchanged or decreased levels of estrogen.80 In multivariate analysis, 
obesity remained an independent prognostic factor for distant recurrence (HR= 1.57; 95% 
CI= 1.11-2.22; p= 0.02). Specifically, in premenopausal women the HR was 1.50 (95% 
CI= 1.00-2.26; p= 0.06) and in postmenopausal women the HR was 2.03 (95% CI= 0.99-
4.21; p= 0.07).80 However, results were not significant but are trending to significance. 
On the other hand, Kroenke and colleagues examined the association between 
BMI and breast cancer recurrence in 5,204 women diagnosed with invasive breast 
cancer.9 After breast cancer diagnosis, if a second cancer was reported (in the lungs, liver, 
bone or brain), it was assumed that breast cancer had recurred. Also, recurrence included 
those women who did not report a second cancer but who died as a result of breast 
cancer. It was assumed that disease recurred two or more years before death. Follow-up 
ranged between 2-26 years, with a median follow-up of nine years. During follow-up, 
681 breast cancer recurrences were observed. Multivariate analysis demonstrated a non-
significant relationship between BMI prior to breast cancer diagnosis. Moreover, results 
were not significant for breast cancer recurrence between obese women (BMI > 30 
kg/m2) and non-obese women (BMI of21-22 kg/m2).9 
2.7.5 Obesity and Breast Cancer-Specific Death 
Zhang and colleagues prospectively studied 698 women diagnosed with postmenopausal 
unilateral breast cancer.81 The study determined whether pre-diagnosis obesity, body fat 
distribution and dietary intake of fats, antioxidants and fibers were associated with 
overall survival and breast cancer-specific death. During a six year follow-up, 56 deaths 
were reported. Of the 56 deaths, 40 had breast cancer among the causes listed on their 
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death certificates. In analysis, restricted to the 40 breast cancer specific-deaths, the 
adjusted RR for the highest (28.8-45.9 kg/m2) vs. lowest (16.0-24.6 kg/m2) terti Ie ofBMI 
was RR= 1.50 (95% CI= 0.70-2.90;p= 0.26).81 Women in the highest tertile ofBMI 
experienced a 50% higher risk of death from breast cancer in comparison to the lowest 
tertile. However this relationship was not significant. A possible explanation for the non-
significant result was the short follow-up and low study power (low number of events). 
Daling and colleagues conducted a population-based survival study, including 
1,177 premenopausal women diagnosed with invasive ductal breast carcinoma.82 The 
outcomes of interest were all cause mortality and breast cancer-specific death. Of the 
1,177 women, 317 deaths were observed and of the 317 deaths, 283 were breast cancer-
specific. Weight one year prior to diagnosis was used to calculate BMI. In analysis, 
women in the highest quartile ofBMI (25.85-52.57 kg/m2) had a 1.70-fold increased risk 
(95% CI= 1.00-2.90; p < 0.05) of breast cancer-specific death compared to the lowest 
quartile ofBMI (15.80-20.64 kglm2). These results were independent of other prognostic 
factors such as age, year at diagnosis, lymph node status and tumor characteristics: tumor 
size, ERiPR status, and alterations in c-erh B-2 oncogene protein, apoptosis regulatory 
protein bcl-2, p53 tumor suppressor gene and cell cycle protein p27.82 
Whiteman and colleagues also examined the relationship between breast cancer-
specific death and factors related to body size such as BMI in adulthood, BMI at age 18 
and weight change from 18 years of age to adulthood.4 During a 14.6 year follow-up, 
1,671 women died. Specifically, 1,347 were recorded as deaths due to breast cancer. In 
analysis, adjusted for age, race, radiation therapy, history of benign breast disease, 
education, menopausal status and stage, obese women (BMI ~ 30.00 kg/m2) were 
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significantly more likely compared to lean women (BMI ::; 22.99 kg/m2) to die from 
breast cancer (HR= 1.34; 95% CI= 1.09-1.65).4 Additionally, women with a BMI of 
25.00-29.99 kg/m2 or 23.00-24.99 kg/m2 had the highest risk of breast cancer death (HR= 
1.25; 95 %CI= 1.08-1.44 and HR= 1.20; 95% CI= 1.04-1.39;p= < 0.0001) compared to 
women with a BMI of::; 22.99 kg/m2.4 Furthermore, Whiteman and colleagues assessed 
whether a J-shaped association was present between BMI and breast cancer-specific 
death. It was observed that women with a BMI of::; 18.50 kg/m2 did not have a breast 
cancer-specific death risk that was significantly different from women with a BMI of 
18.51-22.99 kg/m2 (HR= 1.07; 95% CI = 0.81-1.41). Stratified by menopausal status, the 
association between high BMI and breast cancer-specific death persisted. Therefore, 
results between BMI and premenopausal and postmenopausal breast cancer survival are 
consistent as literature demonstrates a relationship with breast cancer-specific death.9, 10, 
41,68,83 
Lastly, Reeves and colleagues determined the effect of BMI on risk of all cause, 
cardiovascular, competing causes and breast cancer death.84 Interaction terms were 
included to evaluate effect modification by age at diagnosis. The study sample comprised 
of 533 women 2:: 65 years of age at study entry and diagnosed with early and late stage 
breast cancer. During an 8.1 year follow-up, 206 deaths were observed, 45 of which were 
breast cancer-specific. An obese woman at 65 years of age had a five times higher risk of 
death attributed to breast cancer compared to a woman with the same age but with a 
normal BMI (HR= 4.93; 95% CI= 1.12-21.70).84 However, an obese woman at 85 years 
of age had a lower risk of breast cancer-specific death -compared to a woman ofthe same 
age but ofa normal BMI (HR= 0.30; 95% CI= 0.08-1.09).84 This study had limitations. 
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First, the breast cancer-specific death analysis was underpowered because of the small 
number of events resulting in wide confidence intervals. The interaction between BMI 
and age on breast cancer-specific death was borderline statistically significant (p= 0.05) 
and may have reached statistical significance if more events were observed. Also, the 
analysis only took into accountWhite females and women were in generally good health 
at baseline. Thus, these women may not be representative of the general population of 
breast cancer survivors. Finally, important prognostic data such as treatment was not 
available therefore the authors were unable to control for treatment in analysis.84 
2.7.6 Underweightness and Breast Cancer Recnrrence and Breast Cancer-
Specific Survival 
BMI as a prognostic factor remains controversial despite the considerable number of 
studies. The impact ofunderweightness (low BMI) on breast cancer recurrence and death 
has not been adequately addressed because literature has focused primarily at the role of 
high BM1.22, 47, 85 However, literature indicates that underweight populations are at 
increased risk of overall mortality compared to those of normal weight. 86 Thus, it is 
crucial to understand the prognostic significance of low BMI in breast cancer patients 
because this may identify a high-risk subgroup. 
Moon and colleagues explored the prognostic significance of underweight, 
overweight and obesity in Korean breast cancer patients.61 The association between BMI 
and breast cancer recurrence and death was explored using the Korean Breast Cancer 
Registry (KBCR) database and the Seoul National University Hospital Breast Cancer 
Center (SNUHBCC) database. SNUHBCC is a prospectively maintained database 
providing detailed information on the type and date of breast tumor recurrence and last 
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follow-up date. All patients were classified according to the WHO international 
classification system of underweight, nonnal weight and obese. Multivariate Cox 
analyses were conducted to study the prognostic significance between BMI and overall 
survival, breast cancer-specific survival and breast cancer recurrence. Furthennore, 
stratified Cox regression analysis were perfonned for overall and breast cancer-specific 
survival to evaluate the prognostic significance of BMI in each group across stage 
(modeled using the AlCC criteria; stages I-III). 
From the KBCR database, 24,698 patients with non-metastatic, invasive breast 
cancer were identified for whom infonnation on weight and height was collected at time 
of initial diagnosis. Overweight patients had larger tumors, were older at diagnosis and 
had higher frequencies oflymph node metastasis and honnone receptor-negative 
tumors. 61 In multivariate analysis, overweight and obese patients had non-significant 
overall and breast cancer-specific survival differences when compared to nonnal weight 
patients. On the other hand, low BMI was observed to be an independent negative 
prognostic factor for overall survival in multivariate analysis. Also, underweight patients 
had a significantly higher risk of breast cancer-specific survival (HR= 1.49; 95% CI= 
1.15-1.93;p= 0.002).61 Finally, stratifying by stage demonstrated a prognostic effect for 
underweightness across different disease stages. 
Furthennore, to explore the association between BMI and breast cancer 
recurrence, the SNUHBCC database was used because the KBCR did not include time to 
recurrence or type of recurrence. From the SNUHBCC database, 4,345 patients with non-
metastatic, invasive breast cancer with available BMI data were identified. Underweight 
patients showed significant differences in disease-free, distant metastasis-free and local 
39 
recurrence-free survival. However, the difference was highest forlocal recurrence (HR= 
5.13; 95% CI= 2.66-9.90).61 In summary, being underweight was an independent 
prognostic factor for breast cancer survival and for all types of recurrence especially local 
recurrence. However, overweight and obese patients failed to show a significant 
difference in breast cancer recurrence and breast cancer survival. 
Despite the significant findings between BMI and breast cancer outcomes, the 
study had limitations. First, the patients in both databases were heterogeneous in terms of 
disease stage, presence of comorbidities and treatment delivery. Since treatment delivery 
differs according to body weight status, heterogeneous treatment may confound results.61 
Also, the patients included were all of Asian descent. Thus, results are not generalizable 
to other ethnic groups due to body size variations between ethnicities. Finally, the 
nonlinear effect between BMI· and breast cancer outcomes was not described. Additional 
studies need to assess the nonlinear effect ofBMI and breast cancer-specific death. This 
study will describe the nonlinear relationship of BMI and breast cancer 
recurrence/progression and breast cancer-specific death. 
2.8 Nonlinear Relationship between BMI and Breast Cancer Survival and Breast 
Cancer Recurrence 
To date, research has not explored the relationship between BMI and breast cancer-
specific survival. However, the two studies that did evaluate the nonlinear relationship of 
BMI have identified a nonlinear relationship with overall survival and breast cancer 
recurrence.71 ,87 Studying overall survival may hide any relationships that exist specific to 
breast cancer. Despite the fact that literature exploring the association between BMI and 
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overall survival and breast cancer recurrence is available, research should examine this 
relationship with breast cancer-specific death. 
Suissa and colleagues examined the nonlinear relationship between the Quetelet 
index (QI), overall survival and breast cancer recurrence in 68 women diagnosed with 
early stage breast cancer.87 All patients were randomized to receive radical mastectomy, 
total mastectomy with irradiation or total mastectomy with no further treatment. Patient 
medical records were reviewed at time of mastectomy. Body weight was measured using 
the QI, an equivalent measure to the BMI classification system. QI was defined as 0.01 
times the weight in pounds divided by the height squared in inches.87 Cox regression was 
used to examine the association between the QI, overall survival and breast cancer 
recurrence, adjusted for age, stage, menopausal status and treatment. 
First, the QI was modeled as a linear effect. A non-significant relationship was 
observed between the QI and overall survival (p= 0.47). However, when the QI was 
modeled using quadratic terms, a significant association was observed between the QI, 
overall survival and breast cancer recurrence. Also, the hazard function was concave and 
indicative of underweight and overweight status being predictive of an unfavorable 
prognosis of breast cancer. The effect was most evident in those women with a QI of 5 
(overweight). However, the hazard of death was lowest in those women with a QI of3.4 
(normal weight).87 
Despite the significant relationship observed between BMI and overall survival, 
the study contained limitations and results should be interpreted with caution. A major 
flaw was the sample size, which consisted of 68 female breast cancer patients. 
Furthermore, the 68 patients were divided into three treatment groups which would 
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produce unstable estimates of actual survival probabilities by the Kaplan-Meier product 
limit method.87 Instead predicted survival probabilities were reported. Also, there was 
limited emphasis placed on stage because early stage breast cancer cases were only 
eligible. Additionally, effect modification was not assessed. This resulted from the small 
sample size which made it more difficult to detect any interaction effects. Also, the 
methodology contained limitations. The methodology contained minimal description of 
the prognostic variables and no explanation was provided as to how and why these 
variables were included in modeling. Additionally, according to Suissaand colleagues 
and as depicted in Figure 10, the predicted probability of death within five-years of 
diagnosis was almost 100% for a QI of 5. This is misleading and therefore an inaccurate 
depiction of the true five-year mortality rate.87 Finally, study results are in need of 
validation using a larger sample and higher quality epidemiologic study. 
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Figure 10. Predicted Probability of Death within 5 Years of Diagnosis, a Function of 
QI Obtained from the Cox Regression Model. 87 
A similar study was conducted by Goodwin and colleagues who sought to 
confirm the relationship reported by Suissa and colleagues (Figure 10).71,87 Goodwin and 
colleagues validated the aforementioned association using a sample of 512 women 
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diagnosed with early stage breast cancer.71 The median follow-up was 50 months. During 
follow-up, 45 women died however all but three deaths were caused by breast cancer. 
First, the log hazard was modeled linearly. BMI predicted distant disease-free survival 
(p= 0.047) and marginally predicted overall survival (p= 0.063). Then, the relationship 
was modeled using quadratic terms. Modeling BMI using quadratic terms demonstrated a 
significant improvement when compared to the linear model (p < 0.001). Also, it 
identified a significant relationship with distant disease-free and overall survival (p < 
0.001). According to Goodwin and colleagues and as depicted in Figure 11, women with 
a high BMI reported the worst outcomes (BMI > 25 kg/m2). A J-shaped relationship was 
observed; which was also an identical relationship observed by Suissa and colleagues 
(Figure 10).71,87 
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Figure 11. Hazard Ratio Functions for Distant Recurrence and Death, a Function of 
BMI Obtained from the Cox Regression Model.71 
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This study will model BMI using restricted cubic splines as opposed to quadratic 
terms because quadratic terms are not versatile for three reasons: (1) Quadratic terms 
cannot describe sudden changes in shape, (2) Quadratic terms can be unstable where the 
data is thin; usually in extreme ranges such as the tails, and (3) Quadratic terms are not 
capable of describing a great range of nonlinear pattems}6, 88, 89 In this study, greater 
emphasis will be placed on stage, including both early and late stage breast cancer cases. 
Finally, breast cancer-specific death will be the outcome of interest as opposed to overall 
survival. 
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CHAPTER 3: METHODOLOGY 
3.0 Overview 
The current chapter describes the study design, data collection process and statistical 
analysis. The methodology section outlines the study design along with a brief 
description of Henry Ford Health System (HFHS), the place of data collection. Then, the 
type of data abstracted from patient medical records such as sociodemographic, 
clinicopathologic and anthropometric data is discussed. Furthermore, an explanation is 
provided on the outcome data, breast cancer recurrence/progression and breast cancer-
specific death. Finally, this chapter ends with a description of the statistical analysis used 
to address the research questions. 
3.1 Study Design and Context 
The HFHS dataset was originally designed to study comorbidities and racial disparity 
among breast cancer patients. However, the dataset contained necessary breast cancer 
outcome data and relevant anthropometric, clinicopathologic and sociodemographic data. 
Using the HFHS comorbidity database, a historical cohort study design was implemented 
to develop a better understanding of the relationship between BMI and breast cancer 
recurrence/progression and breast cancer-specific death. 
Sample size: Patients were diagnosed with primary breast cancer between 1985 
and 1990 inclusive, at HFHS. In 2002, 906 breast cancer cases were identified from the 
HFHS Tumor Registry, an American College of Surgeons, Commission on Cancer-
certified registry and were included in the study. 
Study context: HFHS is a large, comprehensive, nonprofit system that annually 
provides medical care to more than 500,000 people. Of those, approximately 30% were 
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Black. In 1997, the HFHS patient population distribution in 10 age, 2 race and 2 sex 
categories (40 strata) differed from the metropolitan Detroit (Wayne, Oakland, and 
Macomb counties, 1990 census data) distribution by 5.3% or less in all strata. These 
observations suggest that the HFHS patient population is representative of the community 
it serves.62 
3.2 Study Criteria 
Analysis was limited to Blacks and Whites only. Asians, Pacific Islanders, Native 
Americans and others were excluded because their numbers were too small to permit 
meaningful analysis. Four patients were identified as Hispanic and were included in 
analysis according to the race category they chose (3 White and 1 Black). 
3.3 Research Ethics Approval 
The HFHS institutional review board approved the study. However, the review board 
waived the need to obtain patient consent because the study examined patient medical 
records. The original study was funded by the US Department of Defense (US Army 
Medical Research and Material Command) grant DAMD 17 -00-1-0287. Approval to 
conduct the current secondary data analysis was received from Brock University 
Research Ethics Board. 
3.4 Medical Record Abstraction 
3.4.1 Sociodemographic Data 
Study data were abstracted from patient medical records. Patient medical records were 
abstracted dating back to the patient's presenting symptoms or to the initial visit that 
ultimately led to a breast cancer diagnosis. Sociodemographic data included age, gender, 
race, marital status and socioeconomic status (SES). SES was estimated using block 
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group median household income, derived from the patient's address at breast cancer 
diagnosis and 1990 US census data. Race was classified according to self-report on 
registration forms. 
3.4.2 Clinicopathologic Data 
Exposure and clinicopathologic data included stage, treatment and hormone receptor 
status, which were abstracted directly from patient medical records. Treatment data 
included surgery, radiation therapy and chemotherapy, all analyzed as dichotomous 
variables (received vs. not received). Also, information on type of surgery was collected. 
However, data was not available on treatment completion or dose reduction for 
chemotherapy and radiation therapy. Breast tumor hormone receptor status was 
considered positive if either ER or PR concentrations were> 10 fmol per mg by the 
charcoal dextran assay. ERJPR status was categorized as: negative, positive and 
unknown. Cancer stage, based on pathological stage and in its absence on clinical stage, 
was analyzed according to the AlCC TNM staging system.23 The cancer stage groups 
were treated as dichotomous indicator or "dummy" variables including stages II, Ill, IV 
and unstaged. 
3.4.3 Anthropometric Data 
Anthropometric measurements including weight and height were collected near or at time 
of breast cancer diagnosis by trained study staff at HFHS. Weight was determined using a 
scale. Subject's heights were measured without footwear, with a stadiometer. Weight and 
height were recorded in patient medical records. Later, data pertaining to weight and 
height were directly abstracted from patient medical records and converted to BMI. 
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3.4.4 Survival and Cause-of-Death Data 
Survival follow-up and cause-of-death data were obtained from the HFHS and 
Metropolitan Detroit SEER tumor registries and from Michigan Department of Vital 
Statistics death certificate data. Classification of survival status into the categories alive, 
breast cancer death or competing cause death in the two registries had 91.9% agreement 
and where cause of death data were present in both registries agreement was high- the 
kappa statistic was 0.98.90 The last date of follow-up was May 1,2002. 
3.4.5 Breast Cancer Recurrence/Progression Data 
Data on failure to control cancer, as either local recurrence following resection or 
progression reflected in local expansion or regional or distant spread of cancer, were 
abstracted from patient medical records. 
3.5 Analytic Strategy 
Descriptive statistics were prepared using Fisher's exact test for categorical data, 
nonparametric test of trend for ordinal data, t-test for continuous data in two categories, 
ANOV A for continuous data with more than two categories and difference in follow-up 
using life table analysis (based on the log-rank test). The two goals of modeling were: 
(1) Describe whether BMI was independently associated with breast cancer 
recurrence/progression and breast cancer-specific death, after covariate 
adjustment? 
(2) Determine whether BMI modeled using restricted cubic splines improved 
prediction for breast cancer recurrence/progression and breast cancer-specific 
death? 
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Aim one reflected model development which focused on hypothesis testing in 
which adjustment for confounding and confidence intervals (or p-values) were important. 
In research, hypothesis testing frequently attempts to investigate causality or etiology and 
mechanisms of action. Understanding associations is useful for prevention and 
intervention purposes. 16 
Aim two was based on prediction model development. Prediction model 
development needs to be guided more by the models ability to discriminate and its 
calibration. Gail and Pfeiffer found that in screening applications discriminatory power 
was more importantthan calibration.91 In modeling priority was given to improving 
discrimination, while at the same time attempting to optimize calibration and goodness-
of-fit. 
3.5.1 Modeling BMI Using Restricted Cubic Splines 
It should not be assumed that all relationships involving one or more continuous variables 
are linearly associated. Some biological relationships are nonlinear and more complex. 
Restricted cubic splines are higher order polynomials used in exploring complex 
nonlinear relationships. Restricted cubic splines are superior to splines, cubic splines and 
quadratic tenns because they are able to fit highly curving shapes. 15 As previously 
mentioned, quadratic tenns are not versatile because they cannot describe sudden changes 
in shape and are unstable where data is thin. Also, quadratic tenns are not capable of 
describing a wide range of nonlinear patterns. 89 
Position and number of knots: In choosing the position of the knots, placing 
knots at fixed percentiles is recommended. For example, if five knots are used, they can 
often be placed at the 5th, 25th, 50th, 75th and 95th percentiles. In Stata, placing knots at 
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fixed percentiles is the default option unless specified. However, Stone found that knot 
location is unimportant. The fit depends on the number of knots utilized. 15 Choosing the 
number of knots depend on the sample size and variable distribution. Five knots or 
greater is rarely required in constructing restricted cubic splines. For majority of datasets, 
four knots are adequate and enable a valid comparison between flexibility and loss of 
precision caused by over fitting a small sample. 15 
In both Stata and R statistical programs, the two programs used in this study, 
Harrell's percentile approach was used. In Stata, the mkspline with options cubic and 
nknots command was utilized to construct restricted cubic splines for BMI, using four 
knots and three splines (k-1). In R statistical program, restricted cubic splines for BMI 
were created using the Design and Hmisc libraries produced by Harrell. Specifically, 
using the Irm command and specifying rcs (bmi, 4). The four knots were determined by 
the splines ability to sensibly describe the data based on data distribution percentiles. 
3.5.2 Research Question 1: Are BMI3splines Independently Associated with 
Breast Cancer Outcomes? 
A priori covariates chosen from past literature were: age, stage, ERJPR status, surgery, 
radiation therapy and chemotherapy. Potential confounders such as race, SES, 
menopausal status and family history were assessed in multivariate logistic regression. 
Confounding was assessed by comparing the crude and adjusted estimates of the measure 
of association. If the crude and adjusted measures differed 10-15%, then confounding 
was present. Also, interactions between BMI3splines * race and BMhsplines * menopausal 
status for breast cancer outcomes were assessed. Logistic regression was used to estimate 
odds ratios (OR), 95% confidence intervals (95% CI) and p-values for associations with 
50 
breast cancer recurrence/progression and breast cancer-specific death. However, because 
there was less misclassification of time of death and greater completeness of death data 
compared to recurrence/progression data, study conclusions were based on the death 
analysis. Survival analysis was carried out using Kaplan-Meier,92 life table and Cox 
proportional hazards regression analyses.93 Cox proportional hazards regression was used 
to estimate hazard ratios (HR), 95% CI and p-values for association with breast cancer-
specific death. Since Cox regression uses time-to-event, breast cancer 
recurrence/progression was not assessed in Cox regression because date of 
recurrence/progression was not as accurate as the death data. Cox regression assumptions 
were evaluated graphically (using log minus log survival plots) and statistically (using the 
global test for trend) using Stata estat phtest, rank detail command which tests the 
change in scaled Schoenfeld residuals with time (Appendix 1).94 Log minus log plots 
were created using Stata command stphplot. Compared to logistic regression, Cox 
regression is more powerful in some ways because Cox regression uses time-to-event 
data which utilizes more information. However, Cox regression does not provide specific 
probabilities, which are useful for patients, clinicians and researchers. In this study, the 
HR and OR from modeling were used for comparative purposes and study conclusions 
were based on logistic regression (ORs). 
The association between BMI three splines (BMI3splines) and breast cancer 
recurrence/progression and breast cancer-specific death were evaluated using the 
likelihood ratio test (LRT), which compared the nested model with and without 
BMhsplincs. The LRT was performed using Stata lrtest command. BMhsplines were 
considered to be independently associated with breast cancer recurrence/progression and 
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breast cancer-specific death in logistic and Cox regression ifLRT p:::; 0.05. All reported 
p- values were two-sided. 
3.5.3 Research Question 2: Assessing the Nonlinear Relationship between 
BMI and Breast Cancer Outcomes 
Locally weighted scatter plot smother or lowess is a graphical technique used to fit 
smooth curves to empirical data.95 Lowess is nonparametric because the fitted curve is 
obtained empirically rather than through stringent prior specifications. Lowess plots 
reveal complex relationships that may be easily overlooked with traditional statistical 
modeling procedures such as linear regression. The lowess procedure is often 
conceptualized as a "vertical sliding window" that moves across the horizontal scale axis 
of the scatterplot.95 The window stops and estimates a separate regression equation (using 
weighted least squares) at each of the evaluation points (or knots). Since the regressions 
only involve the data points that fall within the window, the estimated slopes can change 
to follow the contours of the data. In Stata, the default bandwidth is 0.80. Thus 80% of 
the data points that fall within each window are used to estimate theregression equations. 
This feature gives lowess the flexibility to conform to relatively complicated, nonlinear 
shapes within the point cloud of a scatterplot. In Stata, the lowess command was used to 
construct the figures. 
Lowess plots were constructed to graphically describe the relationship between 
BMI and breast cancer outcomes. Also, lowess plots were created to describe the 
relationship between BMI and breast cancer outcomes with advanced and unknown stage 
excluded. This was done because it is believed that those women who lose or lost weight 
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(low BMI) did so because of their advanced disease. Lowess figures with and without 
advanced and unknown stage were compared for similarities and differences. 
To determine the significance of the nonlinear component between BMI and 
breast cancer outcomes R statistical program was used with the specific library Hmisc. 
The anova command yielded the Wald test p-value for nonlinearity. 
3.5.4 Research Question 3: Model Performance (Discrimination, Calibration 
and Validation) 
Breast cancer models were built using a "backward" elimination technique. Breast cancer 
covariates, chosen a prior, predicting breast cancer recurrence/progression and breast 
cancer-specific death included: age, stage, ERiPR status, surgery, radiation therapy, 
chemotherapy, race, SES, menopausal status, family history and BMI3splines. Initially, all 
covariates were included in multivariate logistic regression. Covariates with the highest 
p-value were dropped from breast cancer models. This process was repeated until all 
covariates withp 2: 0.2 were eliminated. Multivariate logistic regression was used to 
determine ifBMbsplines improved the ability to predict breast cancer outcomes. The 
receiver operator characteristic area under the curve (ROC AVC) in logistic regression 
and Harrell's concordance or c-statistic in Cox regression were used to assess the 
discriminatory ability of the breast cancer models. A ROC curve plots the sensitivity 
against the false-positive rate (i.e. one minus the specificity) for a range of thresholds. 
ROC curves for tests with overall good performance will lie close to the left and topmost 
margins of the plot. Stata comproc command was used to test whether there was 
significantimprovement in discrimination for BMbsplines. Comproc tests the null 
hypothesis that the ROC AVC in the model including BMbsplines is equal to the ROC 
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AVC in the model excluding BMl)splines, where models are nested, i.e. include exactly the 
same individuals. Comproc yields bootstrap standard errors and bias-corrected (BC) 95% 
CIs. Bootstrap resampling for comproc was performed using 1000 replications. The c-
statistic takes into account the proportion of all usable subject pairs in which the 
predictions and outcomes are concordant. Then, the c-statistic ranks the hazard, i.e. of 
death, and determines whether this hazard corresponds with those patients who lived 
longer with the outcome. In assessing the c-statistic, a c-statistic of 0.5 is equivalent to 
random or chance discrimination whereas a c-statistic of 1.0 indicates perfect 
discrimination. According to Harrell, a c-statistic > 0.8 is useful in predicting the 
responses of individual subjects. Furthermore, these two measures of discriminatory 
ability have been shown to be mathematically equivalent.96, 97 Harrell's c-statistic was 
performed using Stata e,~tat concordance command. Furthermore, in R statistical 
program using validate and calibrate, Harrell's uncorrected and bootstrap optimism-
corrected c-statistic was calculated using Somer's optimism-corrected Dxy [c-statistic= 
(Dxy/2) + 0.5]. Bootstrapping, an internal validation technique, estimates the sampling 
distribution of an estimator by resampling with replacement from the original sample. 
The difference in the apparent and test validation yields the bootstrap optimism-corrected 
value. Bootstrap optimism-corrected values were performed using 200 replications. IS 
Somer's Dxy looks at the difference between concordant and discordant probabilities. A 
Dxy of 0 indicates that the model is making random predictions whereas a Dxy of 1 
indicates perfectly discriminating predictions. It has been demonstrated that Somer's Dxy 
and Harrell's c-statistic are linearly related and are a measure of a models discriminatory 
ability. 16 
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In addition, overall model performance of the logistic regression models 
predicting breast cancer outcomes were assessed using Nagelkerke's pseudo R2 and the 
Hosmer-Lemeshow goodness-of-fit test. The Hosmer-Lemeshow goodness-of-fit test 
divides subjects into deciles based on predicted probabilities and then computes a chi-
square from the observed and expected frequencies. A Hosmer-Lemeshow goodness-of-
fit test p 2:: 0.05 implies that the models estimates fit the data at an acceptable level. In 
Stata, the estat gof, group (10) command was used to calculate the Hosmer-Lemeshow 
goodness-of-fit-test. 
Finally, calibration assesses how well the predicted probabilities match the 
observed probabilities. Calibration was assessed using the calibration slope, mean 
absolute error and 90th percentile absolute error. The slope summarizes the deviation of 
model predicted probabilities from observed proabbilities. 16 The error in mean absolute 
error and 90th percentile absolute error refers to the difference between the ideal and the 
corresponding bias-corrected calibrated values. In assessing calibration, the three major 
components are: the slope, mean absolute error and 90th percentile absolute error. Thus, a 
larger slope and a smaller error value indicate a well calibrated model. Also, calibration 
plots were created plotting predicted probabilities vs. observed probabilities. Three lines 
define a calibration plot: (1) The ideal line is a 45° line representing a perfectly calibrated 
model with a slope of one, (2) The apparent line is the bootstrap uncorrected line 
depicting the breast cancer models, and (3) The bias-corrected line is the bootstrap 
optimism-corrected line. 15 Calibration was evaluated in R statistical program using the 
Design and Hmisc libraries produced by Harrell with the specific package calibrate. 
55 
Stata/IP 10.1 (Stata Corporation, College Station, Tex) and R (version 2.11.1) 
statistical programs were used to prepare models, statistics and figures. 
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CHAPTER 4: RESULTS 
4.1 Population Demographics 
An initial 906 subjects were included in the study. However, outcome data were available 
for 897 subjects. The population characteristics are provided in Table 4 describing the 
HFHS study population. 
Table 4. Characteristics of the 897 Individuals from HFHS (Detroit, Michigan) 
Characteristics 
Age in years (SD; range) 
Race 
Menopausal status 
Family history 
Follow-up 
Recurrence/progression 
Deaths 
BMI (kg/m2) (SD; range) (N= 816) 
Stage 
Estrogen/progesterone receptor 
Surgery 
Radiation 
Chemotherapy 
Tamoxifen 
White 
Black 
Premenopausal 
Postmenopausal 
No 
Yes 
Unknown 
Median (range) in years 
No 
Yes 
Unknown 
No 
Breast cancer 
Competing causes 
Carcinoma in situ 
I 
II 
III 
IV 
Unstaged 
Negative 
Positive 
Unknown 
No 
Yes 
Unknown 
No 
Yes 
Unknown 
No 
Yes 
Unknown 
No 
Yes 
Unknown 
HFHS patients (N= 897) 
60.7 (14.S; 24-94) 
634 (70.7%) 
263 (29.3%) 
178 (19.8%) 
719 (80.2%) 
388 (43.3%) 
235 (26.2%) 
274 (30.5%) 
10.0 (0.04-17.8) 
518 (57.7%) 
281 (31.3%) 
98 (10.9%) 
418 (46.6%) 
180 (20.1%) 
299 (33.3%) 
27.2 (6.3; 15.1-55.8) 
30 (3.3%) 
282 (31.4%) 
378 (42.1%) 
91 (10.1%) 
48 (5.4%) 
68 (7.7%) 
114 (12.7%) 
514 (57.3%) 
269 (30.0%) 
40 (4.5%) 
818 (91.2%) 
39 (4.3%) 
563 (62.8%) 
256 (28.5%) 
78 (8.7%) 
566 (63.1%) 
245 (27.3%) 
86 {9.6%} 
469 (52.3%) 
346 (38.6%) 
82 (9.1%) 
Abbreviations: BMI, body mass index; N, sample size; SD, standard deviation. 
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The mean age at breast cancer diagnosis was 60.7 years and mean BMI, at 
diagnosis, was 27.2 kglm2. Majority (76.8%) of patients were diagnosed with early stage 
breast cancer (Stage 0-11). ERiPR status was as follows: 114 (12.7%) patients were 
ERiPR negative whereas 514 (57.3%) patients were ERIPR positive. Eight hundred 
eighteen (91.2%) patients underwent surgery whereas 40 (4.5%) did not. Also, 256 
(28.5%) received radiation therapy compared to 563 (62.8%) of patients who did not. 
Finally, 245 (27.3%) received chemotherapy whereas 566 (63.1 %) did not. The median 
follow-up was 10 years (range 0.04-17.8). During follow-up, 281 patients experienced a 
breast cancer recurrence/progression and 180 breast cancer-specific deaths were reported. 
The distribution of breast cancer recurrence/progression and breast cancer status 
by baseline characteristics for selected variables is presented in Tables 5 and 6, 
respectively. 
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Table 5. Breast Cancer Recurrence/Progression in HFHS Patients (Detroit, 
Michigan), by Baseline Characteristics (N= 799) 
Characteristics 
Age in years {SO; range} 
Race 
White 
Black 
Menopausal status 
Premenopausal 
Postmenopausal 
Family history 
No 
Yes 
Follow-up 
Median {range} in years 
8MI (kg/mz) {SO; range} {N= 742} 
Stage 
Carcinoma in situ 
I 
II 
III 
IV 
Unstagedt 
Estrogen/progesterone receptor 
Negative 
Positive 
Surgery 
Radiation 
No 
Yes 
No 
Yes 
Chemotherapy 
No 
Yes 
Tamoxifen 
No 
Yes 
No (N= 518) 
60.4 {14.4; 24-93} 
376 {67.6%} 
142 {58.4%} 
109 (66.5%) 
409 {64.4%} 
243 {68.1%} 
147 {67.4%} 
10.8 {0.04-17.8} 
27.3 {6.2; 16.3-53.8} {N= 487} 
24 {100%} 
212 {84.5%} 
227 {65.2%} 
29 {34.1%} 
2 {4.3%} 
24 {53.3%} 
54 {49.5%} 
306 {67.4%} 
9 {23.7%} 
508 {67.6%} 
368 {70.4%} 
135 {57.0%} 
382 {73.6%} 
117 {50.0%} 
312 {71.6%} 
191 {58.8%} 
Yes (N= 281) 
60.5 {14.8; 26-94} 
180 {32.4%} 
101 {41.6%} 
55 {33.5%} 
226 {35.6%} 
114 {31.9%} 
71 {32.6%} 
5.1 {0.04-17.6} 
27.1 {6.7; 15.1-55.8} {N= 255} 
39{1~.5%} ] 
121 {34.8%} 
56 {65.9%} 
44 {95.7%} 
21 {46.7%} 
55 {50.5%} 
148 {32.6%} 
29 {76.3%} 
243 {32.4%} 
155 {29.6%} 
102 {43.0%} 
137 {26.4%} 
117 {50.0%} 
124 {28.4%} 
134 {41.2%} 
Abbreviations: BMI, body mass index; N, sample size; SD, standard deviation. 
PValue* 
0.89 
0.02 
0.65 
0.93 
< 0.001 
0.64 
< 0.001 
0.11 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
* P values were computed for dichotomous variables using the Fisher exact test, for age and BMI using the 
t test, for follow-up using life-table analysis (based on the log-rank test) and stage using the nonparametric 
test for trend. 
t Unstaged is not included in the nonparametric test for trend; assessing whether a significant difference 
exists in unstaged breast cancer between those women who did not and did experience a breast cancer 
recurrence/progression. 
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As depicted in Table 5, there was no significant difference in age between those 
subjects who did not experience breast cancer recurrence/progression from those who 
did. Subjects who did not experience breast cancer recurrence/progression had a 
significantly longer follow-up (median 10.8 years) when compared to subjects who 
experienced recurrence/progression from breast cancer (median 5.1 years; log-rank testp 
< 0.001 testing the difference of the entire survival experience of both groups). There was 
no significant difference in BMI between subjects who did and did not experience breast 
cancer recurrence/progression. A significant trend was observed for breast cancer 
recurrence/progression across the ordered levels of stage (p < 0.001). There was a 
significant difference in ERIPR status between subjects without and with breast cancer 
recurrence/progression (p < 0.001). Finally, there was a significant difference in surgery, 
radiation therapy, chemotherapy and tamoxifen between subjects without and with 
recurrence/progression from breast cancer (p < 0.001). 
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Table 6. Death Status in HFHS Patients (Detroit, Michigan), by Baseline Characteristics (N= 897) 
Characteristics Alive (N= 418) 
Age in years (SD; range) 55.0 (12.5; 24-83) 
Race 
White 316 (49.8%) 
Black 102 (38.8%) 
Menopausal status 
Premenopausal 123 (69.1%) 
Postmenopausal 295 (41.0%) 
Family history 
No 201 (51.8%) 
Yes 126 (53.6%) 
Follow-up 
Median (range) in years 12.7(0.08-17.8) 
BMI (kg/m2) (SD; range) (N= 816) 27.1 (5.8; 16.3-53.8) (N= 389) 
Stage 
Carcinoma in situ 22 (73.3%) 
167 (59.2%) 
II 177 (46.8%) 
III 20 (21.9%) 
IV 1 (2.1%) 
Unstagedt 31 (45.6%) 
Estrogen/progesterone receptor 
Negative 45 (39.5%) 
Positive 239 (46.5%) 
Surgery 
No 3(7.5%) 
Yes 399 (48.8%) 
Radiation 
No 266 (47.3%) 
Yes 121 (47.3%) 
Chemotherapy 
No 262 (46.3%) 
Yes 125 (51.0%) 
Tamoxlfen 
No 244 (52.0%) 
Yes 143 (41.3%) 
Competing causes death (N= 299) 
69.1 (13.3; 26-94) 
203 (32.0%) 
96 (36.5%) 
11 (6.2%) 
288 (40.1%) 
114 (29.4%) 
58 (24.7%) 
6.3 (0.04-16.4) 
27.6 (6.7; 16.3-53.3) (N= 269) 
8 (26.7%) 
94 (33.3%) 
124 (32.8%) 
29 (31.9%) 
21 (43.7%) 
23 (33.8%) 
19 (16.7%) 
164(31.9%) 
23 (57.5%) 
262 (32.0%) 
205 (36.4%) 
65 (25.4%) 
228 (40.3%) 
39 (15.9%) 
141 (30.1%) 
125 (36.1%) 
Abbreviations: BMI, body mass index; N, sample size; SO, standard deviation. 
Breast cancer-specific death (N= 180) 
60.1 (14.0; 30-90) 
115 (18.2%) 
65 (24.7) 
44 (24.7%) 
136 (18.9%) 
73(18.8%) 
51 (21.7%) 
3.3 (0.05-15.7) 
26.6 (6.9; 15.1-55.8) (N= 158) 
'J 21 (7.5%) 77 (20.4%) 42 (46.2%) 
26 (54.2%) 
14 (20.6%) 
50(43.8%) 
111 (21.6%) 
14 (35.0%) 
157 (19.2%) 
92 (16.3%) 
70 (27.3%) 
76 (13.4%) 
81 (33.1%) 
84(17.9%) 
78(22.6%) 
PVaiue* 
< 0.001 
0.006 
< 0.001 
0.39 
< 0.001 
0.31 
< 0.001 
0.97 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
0 .01 
* P values were computed for categorical variables using contingency table analysis (and Fisher exact test), for age and BMI using AN OVA, for follow-up using 
life-table analysis (based on the log-rank test) and stage using the nonparametric test for trend. 
t Unstaged is not included in the nonparametric test for trend; assessing whether a significant difference exists in unstaged breast cancer between those 
women who survived, died due to competing causes and due to breast cancer-specific death. 
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In evaluating death status by baseline characteristics, there was a significant 
difference in age between those who survived, died due to competing causes and died due 
to breast cancer-specific death. Those who died from breast cancer had a shorter follow-
up (median 3.3 years) compared to those who died from competing causes (median 6.3 
years; log-rank testp < 0.001 testing the difference ofthe entire survival experience of 
both groups). There was no significant difference in BMI between those subjects who 
survived, died of competing causes and died due to breast cancer-specific death. A 
significant trend was observed between those who survived, died of competing causes 
and died due to breast cancer-specific death across the ordered levels of stage (p < 0.001). 
In assessing hormone receptor status, there was a significant difference in ERiPR status 
between those subjects who survived, died due to competing causes and died from breast 
cancer-specific death (p < 0.001). Finally, there was a significant difference in surgery, 
radiation therapy and chemotherapy between those subjects who survived, died of 
competing causes and died due to breast cancer-specific death (p< 0.001). 
The distribution of baseline characteristics for selected variables by BMI 
categories are presented in Table 7. 
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Table 7. Baseline Characteristics of the HFHS (Detroit, Michigan) Study Population, 
by BMI Categories (N= 816) 
Characteristics* < 22 kg/m2 22-25 kg/m2 > 25-30 kg/m' ~30kgfm2 P 
IN= 163) IN= 194) IN=246) (N= 213) Value* 
Age in years (SO; range) 59.2 (16:3; 24-94) 60.1 (i5.5; 31~9W · 61.6 (12.8; 30' 93) - . 61 .4(13~2; 28~88) 0.32 
Race 
White 134 (82.2%) 157(80.9%) 166 (67.5%) 121 (56.8%) <0.001 
Black 29 (17.8%) 37 (19.1%) 80 (32.5%) 92 (43.2%) 
Menopausal status 
PrerTI,;nopausal. 40 (24.5~) 50 (25.8%) 37-(1fO~) : 34(16.0%) ~.:Ol 
Postmenopausal 123 (7S~5%) 144(74.2%) 20.9 (85.0%) 179(84.0%) 
Family history 
No 72 (55.0%) 99 (65.6%) 110 (62.2%) 101 (64.3%) 0.28 
Yes 59 (45.0%) 52 (34.4%) 67 (37.8%) 56 (35.7%) 
FollOW-lip 
Median (range) in years 8.6 (0.05-17.0) 11.2 (0.04-17.8) 10.8 (0.08-11.4) 9.8 (0.25-17.7) 0.27 
Stage 
Carcinoma in situ 4(2.4%) 12 (6.2%) 7(2.8%) 
4(1.8%) J 
I 55 (33.7%) 72 (37.1%) 82 (33.3%) 59 (27.7%) 
II 65 (39.9%) 73 (37.7%) 109 (44.3%) 105 (49.3%) 0.16 
III 15 (9.2%) 21 (10.8%) 23 (9.3%) 24 (11.3%) 
IV 13 (8.0%) 7(3.6%) 12 (5.0%) 13 (6.1%) 
Unstagedt 11 (6.8%) 9(4.6%) 13 (5.3%) 8(3.8%) 0.61 
23 (16;"l~) 
No 10 (6.2%) 5(2.6%) 7(2.9%) 13 (6.2%) 0.13 
Yes 152 (93.8%) 186 (97.4%) 235 (97.1%) 198(93.8%) 
Radiation 
't' 
)11 (7l.6%) 
(~8'1~h £2 ~5 (35)%) '~;;';, ",!;, .,,,,.,.c, ,,,.x._, ,;0il 
Chemotherapy 
No 104 (67.1%) 131 (73.2%) 161 (70.9%) 134(67.0%) 0.50 
Yes 51 (32.9%) 48 (26.8%) 66 (29.1%) 66 (33.0%) 
5:(;", } 
' 107, (52.2%) . 5:,.r-,:, _c"': 
9~(47.8'!f>~ 
Alive 66 (40.5%) 104 (53.6%) 122 (49.6%) 97 (45.5%) 
Competing causes 54(33.1%) 54(27.8%) 84 (34.1%) 77 (36.2%) 0.08 
Breast cancer 43 (26.4%) 36(18.6%) 40 (16.3%) 39(18.3%) 
Abbreviations: BMI, body mass index; N, sample size; SD, standard deviation. 
* P values were computed for categorical variables using contingency table analysis (Fisher exact test), for 
age and BMI using ANOV A, for follow-up using life-table analysis (based on the log-rank test) and stage 
using the nonparametric test for trend. 
t Unstaged is not included in the nonparametric test for trend; assessing whether a significant difference 
exists in unstaged breast cancer between BMI categories. 
t In this table column percentages are reported. 
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As depicted in Table 7, there was no significant difference in age, family history, 
follow-up, stage, ERiPR status, surgery, radiation therapy, chemotherapy and tamoxifen 
and death status between those women who were underweight, normal weight, 
overweight and obese near or at breast cancer diagnosis. However, there was a significant 
difference in race and menopausal status between those women who were underweight, 
normal weight, overweight and obese near or at breast cancer diagnosis (P < 0.001 and p= 
0.01, respectively) 
4.2 Covariates Included in the Breast Cancer Recurrence/Progression Model 
4.2.1 Unadjusted Logistic Regression 
A priori covariates used in the breast cancer recurrence/progression model are presented 
in Table 8. 
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Table 8. Unadjusted Logistic Regression Odds Ratios for Breast Cancer 
Recurrence/Progression (N =799) 
Characteristics 
Age (per 10 years) 
Stage Carcinoma in situ + stage I 
Stage II 
Stage III 
Stage IV 
Unstaged 
Estrogen/progesterone receptor Negative 
Treatment 
8MI (N= 742) 
Positive 
Unknown 
Surgery (N= 789) 
Radiation (N= 760) 
Chemotherapy (N= 753) 
Spline l' 
Spline 2-
Spline 3-
Abbreviations: BMI, body mass index; N, sample size. 
HFHS patients 
1.01 (0.91-1.11; p= 0.89) 
Baseline 
3.23 (2.15-4.83; P < 0.001) 
11.69 (6.66-20.50; P < 0.001) 
133.13 (31.01-571.52; p < 0.001) 
5.29 (2.69-10.42; P < 0.001) 
Baseline 
0.47 (0.31-0.73; P < 0.001) 
0.48 (0.31-0.77; p= 0.002) 
0.15 (0.07~0.32; P < 0.001) 
1.79 (1.30-2.47; P < 0.001) 
2.79 (2.02-3.85; P < 0.001) 
0.81 (0.71-0.93; p= 0.002) 
2.38 (1.25-4.52; p= 0.008) 
0.13 (0.03-0.66; p= 0.013) 
* Knot location for BMI3splines: 19.22 kg/m2, 23.96 kg/m2, 28.29 kg/m2 and 38.44 kg/m2. 
Stage, ERIPR status, surgery, radiation therapy and chemotherapy were associated 
with breast cancer recurrence/progression in unadjusted analysis (p < 0.001). However, 
age was not associated with breast cancer recurrence/progression in unadjusted logistic 
regression (p= 0.89). 
4.2.2 Multivariate Logistic Regression 
In Table 9, multivariate logistic regression independent variables effect estimates, 95% 
CIs and p-values are presented for breast cancer recurrence/progression. 
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Table 9. Multivariate Logistic Regression Odds Ratios and Performance Statistics 
for Breast Cancer Recurrence/Progression (N= 692) 
Characteristics HFHS patients 
1.24 (1.06-1.44; p= 0.01) Age (per 10 years) 
Stage Carcinoma in situ + stage I Baseline 
Stage II 3.43 (2.10-5.60; P < 0.001) 
Stage III 10.50 (5.41-20.39; P < 0.001) 
Stage IV 
Unstaged 
Estrogen/progesterone receptor Negative 
Treatment 
BMI 
Positive 
Unknown 
Surgery 
Radiation 
Chemotherapy 
Spline l' 
Spline 2-
Spline 3-
MODEL PERFORMANCE 
LRT p-value for BMI3spiines 
Nonlinear p-value 
ROC AUC w & wlo BMI3spiines 
Comparison of ROC summary statistics w & wiD BMI3spiines 
R2 
Hosmer-Lemeshow goodness-of-fit-test 
c-statistic 
Calibration 
Calibration slope 
Mean absolute error 
90th percentile absolute error 
95.36 (21.11-430.80; P < 0.001) 
2.75 (1.09-6.93; p= 0.03) 
Baseline 
0.62 (0.36-1.08; p= 0.09) 
0.58 (0.32-1.04; p= 0.07) 
0.20 (0.06'-0.60; p= 0.004) 
2.04 (1.36-3.08; p= 0.001) 
2.43 (1.51-3.94; P < 0.001) 
0.77 (0.65-0.92; p= 0.003) 
3.00 (1.35-6.68; p= 0.01) 
0.07 (0.01-0.52; p= 0.01) 
p= 0.0230 
p= 0.0194 
0.8006; 0.7929 
AUC delta= 0, p= 0.14 
t * 0.364 ; 0.322 
p= 0.699 
0.801; 0.782* 
0.883* 
0.018 
0.038 
Abbreviations: BMI, body mass index; LRT, likelihood ratio test; N, sample size; ROe AUe, receiver 
operator characteristic area under the curve. 
* Knot location for BMI3splines: 19.22 kg/m2, 23 .96 kg/m2, 28.29 kg/m2 and 38.44 kg/m2. 
t Nagelkerke's R2. 
t Bootstrap optimism-corrected R2, c-statistic and calibration slope obtained using Harrell's validate and 
calibrate function in R. 
Note: Race, SES, menopausal status and family history were tested in the breast cancer 
recurrence/progression model and deemed unimportant and are therefore excluded from modeling. 
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In multivariate logistic regression, age was significantly associated with breast 
cancer recurrence/progression (p= 0.01). However, age was not significant in unadjusted 
analysis. Stage was highly associated with breast cancer recurrence/progression in both 
unadjusted and multivariate analysis (p < 0.001). ERiPR status was not significant in 
multivariate logistic regression however results were trending to significance. On the 
other hand, ERiPR status was significant in unadjusted logistic regression. Finally, 
surgery, radiation therapy and chemotherapy remained significant in both unadjusted and 
multivariate analysis. 
4.2.2.1 Testing of Relevant Covariates for Breast Cancer 
Recurrence/Progression 
Co variates: Aside from the well-established breast cancer covariates, other variables 
from past literature were tested including race, menopausal status and SES. When race 
was added to the multivariate model in Table 9, it was not significant (p= 0.08). 
However, it was trending to significance. Similarly, menopausal status and SES in 
multivariate logistic regression were not significantly associated with breast cancer 
recurrence/progression (p= 0.96 and p= 0.89, respectively). 
Interaction terms: Possible interaction terms between BMI3spiines * race and 
BMI3spiines * menopausal status were evaluated. BMbsplincs * race and BMI3spiines * 
menopausal status as interaction terms were not significantly associated with breast 
cancer recurrence/progression (p= 0.50 and p= 0.12, respectively). 
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4.2.3 Research Question 1: BMI3splines and Breast Cancer 
Recurrence/Progression 
According to the LRT (Table 9), BMI3spiines were independently associated with breast 
cancer recurrence/progression (p= 0.023). 
4.2.4 Research Question 2: Assessing the Nonlinear Association between 
BMI3splines and Breast Cancer Recurrence/Progression 
A lowess curve describing the nonlinear relationship between BMI3spiines and breast 
cancer recurrence/progression is presented in Figure 12. Also, a lowess curve describing 
the nonlinear relationship between BMI3spiincs and breast cancer recurrence/progression 
with advanced and unknown stage excluded is presented in Figure 13 . 
• 
10 15 20 
bandwidth = .8 
25 30 35 40 
Body Mass Index 
45 50 55 60 
Figure 12. Lowess Curve Describing the Relationship between BMI3spiines and Breast 
Cancer Recurrence/Progression in the HFHS (Detroit, Michigan) Data 
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Figure 13. Lowess Curve Describing the Relationship between BMI3spiines and Breast 
Cancer Recurrence/Progression with Advanced and Unknown Stage Excluded 
According to Figure 12, the probability of breast cancer recurrence/progression 
increased with decline in BMI from roughly 25 kg/m2 and increased with increase in BMI 
from the above mentioned BM!. The increase in probability was evident from a BMI of 
25-35 kg/m2• Then a leveling off and a possible slight decline in the probability of breast 
cancer recurrence/progression with increasing BMI was observed. The increase in 
probability appeared to be higher for low BMI as opposed to high BML This effect might 
have been explained away by those patients with advanced stage breast cancer losing 
weight (BMI) due to their advanced disease. For this reason analysis was limited to early 
stage breast cancer cases « stage III) only (Figure 13); the nonlinear effect appeared to 
be remarkably similar in shape to Figure 12. The Wald test p-value assessing nonlinearity 
between BMI and breast cancer recurrence/progression was p= 0.02; indicating a 
significant nonlinear association between BMI and breast cancer recurrence/progression. 
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4.2.5 Research Question 3: Testing Model Performance for the Model 
Predicting Breast Cancer Recurrence/Progression 
As depicted in Table 9, the bootstrap bias-corrected (BC) estimates assessing the ROC 
AVC in the nested model with and without BMhsplines were 0.8006 (bootstrap SE 0.02; 
BC 95% CI= 0.76-0.83) and 0.7929 (bootstrap SE 0.02; BC 95% CI= 0.76-0.83). 
Although not statistically significant at the 0.05 level, the results are trending to 
significance (p= 0.14) and are suggestive ofa possible difference in the ROC AVCs. A 
ROC AVC comparing the nested model with and without BMI3splines is presented in 
Figure 14. 
0.00 0.25 0.50 
1-Specificity 
0.75 1.00 
• wBMlspline ROC area: 0.8006. noBMlspline ROC area: 0.79 9 
--- Reference 
Figure 14. ROC Curve for Breast Cancer Recurrence/Progression in the Nested 
Model with and without BMI3splines in the HFHS (Detroit, Michigan) Data 
The uncorrected and bootstrap optimism-corrected c-statistics predicting breast 
cancer recurrence/progression were 0.801 and 0.782. As a result, the model predicting 
breast cancer recurrence/progression demonstrated good discriminatory ability between 
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those subjects who did not and did experience a recurrence/progression from breast 
cancer. The model predicting breast cancer recurrence/progression had a pseudo R2 of 
0.364 and a bootstrap optimism-corrected pseudo R2 of 0.322. Furthermore, the Hosmer-
Lemeshow goodness-of-fit testp-value was 0.699, implying that the model's estimates fit 
the data at an acceptable level. 
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Figure 15. Calibration Plot Predicting Breast Cancer Recurrence/Progression 
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A calibration plot (plotting the predicted probabilities vs. observed probabilities) is 
presented in Figure 15. In assessing the calibration plot, the calibration slope of the 
prognostic model is 0.883. Also, the mean absolute error (0.018) and 90th percentile 
absolute error (0.038) are small. This indicates that the model predicting breast cancer 
recurrence/progression is well calibrated as measured by the calibration slope, mean 
absolute error and 90th percentile absolute error. 
4.3 Inclusion of Covariates in the Breast Cancer-Specific Death Model 
4.3.1 Unadjusted Logistic Regression 
A priori covariates from previous literature in unadjusted logistic regression are presented 
in Table 10. 
Table 10. Unadjusted Logistic Regression Odds Ratios for Breast Cancer-Specific 
Death (N= 897) 
Characteristics 
Age (per 10 years) 
Stage Carcinoma in situ + stage I 
Stage II 
Stage III 
Stage IV 
Unstaged 
Estrogen/progesterone receptor Negative 
Treatment 
8MI (N= 816) 
Positive 
Unknown 
Surgery (N= 858) 
Radiation (N= 819) 
Chemotherapy (N= 811) 
Spline 1* 
Spline 2* 
Spline 3* 
Abbreviations: BMI, body mass index; N, sample size. 
HFHS patients 
0.97 (0.86-1.08; p= 0.54) 
Baseline 
3.54 (2.13-5.90; P < 0.001) 
11.88 (6.49-21.75; P < 0.001) 
16.38 (7.97-33.65; P < 0.001) 
3.59 (1.72-7.50; p= 0.001) 
Baseline 
0.35 (0.23-0.54; P < 0.001) 
0.10 (0.05-0.18; P < 0.001) 
0.44 (0.23-0.86; p= 0.02) 
1.93 (1.35-2.75; P < 0.001) 
3.18 (2.22-4.56; P < 0.001) 
0.84 (0.73-0.96; p= 0.01) 
1.77 (0.89-3.52; p= 0.10) 
0.30 (0.05-1.67; p= 0.17) 
* Knot location for BMI3splines: 19.22 kg/m2, 23.96 kg/m2, 28.29 kg/m2 and 38.44 kg/m2. 
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In unadjusted analysis, age was not significantly associated with breast cancer-
specific death (p= 0.54). Stage was highly associated with breast cancer-specific death. 
Patients in stage IV of their disease had 16.38-fold greater odds of dying from breast 
cancer compared to patients with carcinoma in situ and stage I (p < 0.001). In assessing 
hormone receptor status, ERiPR status was significantly associated with breast cancer-
specific death. Subjects with ERiPR positive hormone status had 0.35-fold lower odds of 
dying from breast cancer compared to patients with ERiPR negative hormone status (p < 
0.001). Surgery, radiation therapy and chemotherapy were significantly associated with 
breast cancer-specific death. 
4.3.2 Multivariate Logistic Regression 
Well established covariates associated with breast cancer-specific death were forced into 
multivariate logistic regression. Effect estimates, associated 95% CIs and p-values are 
presented in Table 11. 
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Table 11. Multivariate Logistic Regression Odds Ratios and Performance Statistics 
for Breast Cancer-Specific Death (N= 743) 
Characteristics 
Age (per 10 years) 
Stage Carcinoma in situ + stage I 
Stage II 
Stage III 
Stage IV 
Unstaged 
Estrogen/progesterone receptor Negative 
Treatment 
8MI 
Positive 
Unknown 
Surgery 
Radiation 
Chemotherapy 
Spline 1* 
Spline 2* 
Spline 3* 
MODEL PERFORMANCE 
LRT p-value for BMI3spiines 
Nonlinear p-value 
ROC AUC w & wlo BMI3spiines 
Comparison of ROC summary statistics w & wlo BMI3spiines 
R2 
Hosmer-Lemeshow goodness-of-fit-test 
c-statistic 
Calibration 
Calibration slope 
Mean absolute error 
90th percentile absolute error 
HFHS patients 
1.32 (1.10-1.58; p= 0.002) 
Baseline 
3.40 (1.79-6.46; p < 0.001) 
11.31 (5.16-24.78; P < 0.001) 
18.82 (7.23-48.98; P < 0.001) 
1.92 (0.48-7.76; p= 0.36) 
Baseline 
0.53 (0.30-0.93; p= 0.03) 
0.09 (0.04-0.18; P < 0.001) 
1.12 (0.38-3.30; p= 0.84) 
2.31 (1.44-3.69; P < 0.001) 
3.86 (2.24-6.66; P < 0.001) 
0.78 (0.66-0.93; p= 0.01) 
2.21 (0.95-5.14; p= 0.07) 
0.18 (0.02-1.51; p= 0.12) 
p= 0.0101 
p= 0.0121 
0.8424; 0.8331 
AUC delta= 0, p= 0.08 
0.374t ; 0.327* 
p= 0.210 
0.842; 0.824* 
0.892* 
0.025 
0.050 
Abbreviations: BMI, body mass index; LRT, likelihood ratio test; N, sample size; ROe Ave, receiver 
operator characteristic area under the curve. 
* Knot location for BMI3splines: 19.22 kg/m2, 23.96 kg/m2, 28.29 kg/m2 and 38.44 kg/m2. 
t Nagelkerke's R2. 
t Bootstrap optimism-corrected R2, c-statistic and calibration slope obtained using Harrell's validate and 
calibrate function in R. 
Note: Race, SES, menopausal status and family history were tested in the breast cancer-specific death 
model and deemed unimportant and are therefore excluded from modeling. 
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Age, in the multivariate model (Table 11), was significantly associated with 
breast cancer-specific death. For every 10 year increase in age those women diagnosed 
with breast cancer had a 32% greater odds of dying from breast cancer (p= 0.002). Stage 
adjusted for all covariates was significantly associated with breast cancer-specific death. 
Women with stage IV disease had 18.82-fold greater odds of dying from breast cancer 
compared to women who had carcinoma in situ and stage I (p < 0.001). ERiPR positive 
hormone status compared to ERiPR negative hormone status demonstrated a protective 
effect of breast cancer-specific death (OR= 0.53;p= 0.03). Surgery was not significantly 
associated with breast cancer-specific death (p= 0.84) whereas radiation therapy and 
chemotherapy were significantly adversely associated with breast cancer-specific death 
(p < 0.001). 
4.3.2.1 Testing of Additional Covariates for Breast Cancer-Specific Death 
Covariates: Additional sociodemographic and clinical covariates deemed important were 
assessed in multivariate logistic regression. Inclusions of covariates were guided by past 
literature. Race, adjusted for age, stage, ERiPR status, surgery, radiation therapy, 
chemotherapy and BMI3splines was not significantly associated with breast cancer-specific 
death (p= 0.24). Similarly, SES, adjusted for the above mentioned covariates was not 
significantly associated with breast cancer-specific death (p= 0.98). Finally, menopausal 
status was not significantly associated with breast cancer-specific death (p= 0.67). 
Interaction terms: Interaction terms between BMhsplines * race and BMI3splines * 
menopausal status were created and tested for breast cancer-specific death. BMhsplines * 
race and BMI3splines * menopausal status were not significantly associated with breast 
cancer-specific death (p= 0.48 and p= 0.25, respectively). 
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4.3.3 Covariates Included in Multivariate Cox Regression for Breast Cancer-
Specific Death 
In assessing breast cancer-specific death, a multivariate Cox regression model is 
presented in Table 12. 
Table 12. Multivariate Cox Regression Hazard Ratios for Breast Cancer-Specific 
Death (N= 743) 
Characteristics 
Age (per 10 years) 
Stage 
Estrogen/progesterone ·receptor 
Treatment 
BMI 
Carcinoma in situ + stage I 
Stage II 
Stage III 
Stage IV 
Unstaged 
Negative 
Positive 
Unknown 
Surgery 
Radiation 
Chemotherapy 
Spline 1 * 
Spline 2* 
Spline 3* 
MODEL PERFORMANCE 
LRT p-value for BMI3spiines 
c-stati sti c 
Abbreviations: BMI, body mass index; N, sample size. 
HFHS patients 
1.31 (1.13-1.52; P < 0.001) 
Baseline 
3.37 (1.88-6.04; P < 0.001) 
7.81 (4.10-14.88; P < 0.001) 
29.38 (14.05-61.45; P < 0.001) 
2.02 (0.58-7.07; p= 0.27) 
Baseline 
0.65 (0.43-0.98; p= 0.04) 
0.26 (0.15-0.47; P < 0.001) 
1.46 (0.66-3.25; p= 0.35) 
2.27 (1.58-3.28; P < 0.001) 
2.61 (1.72-3.95; P < 0.001) 
0.75 (0.66-0.86; P < 0.001) 
2.87 (1.48-5.857; p= 0.002) 
0.09 (0.02-0.48; p= 0.01) 
p= 0.0003 
0.82 
* Knot location for BMI3splines: 19.22 kg/m2, 23.96 kg/m2, 28.29 kg/m2 and 38.44 kg/m2. 
Note: Race, SES, menopausal status and family history were tested in the breast cancer-specific death 
model and deemed unimportant and are therefore excluded from modeling. 
Age, adjusted for the aforementioned covariates was significantly associated with 
breast cancer-specific death (p < 0.001). Stage was highly associated with breast cancer-
specific death. Women with stage IV disease had 29.38-fold greater hazard of death from 
breast cancer compared to women who had carcinoma in situ and stage I (p < 0.001). 
ERiPR positive status was associated with breast cancer-specific death (p= 0.04). Finally, 
surgery was not significantly associated with breast cancer-specific death whereas 
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radiation therapy and chemotherapy were highly adversely associated with breast cancer-
specific death (p < 0.001). 
The Cox regression model was used to determine if effect estimates were 
consistent with logistic regression effect estimates. Effect estimates and standard errors 
were consistent between Cox and logistic regression models. For this reason, study 
conclusions are based on logistic models as presented. 
4.3.4 Research Question 1: BMI3splines and Breast Cancer-Specific Death in 
Multivariate Logistic Regression 
According to the LRT (Table 11), BMhsplines were independently associated with breast 
cancer-specific death (p= 0.0101). 
4.3.5 Research Question 2: Assessing the Nonlinear Association between 
BMI3splines and Breast Cancer-Specific Death 
A lowess curve describing the nonlinear relationship between BMI3spiines and breast 
cancer-specific death is presented in Figure 16. A lowess curve describing the nonlinear 
relationship between BMI3spiines and breast cancer-specific death with advanced and 
unknown stage excluded is presented in Figure 17. 
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Figure 16. Lowess Curve Describing the Relationship between BMI3splines and Breast 
Cancer-Specific Death in the HFHS (Detroit, Michigan) Data 
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Figure 17. Lowess Curve Describing the Relationship between BMI3spiines and Breast 
Cancer-Specific Death with Advanced and Unknown Stage Excluded 
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As depicted in Figure 16, the probability of breast cancer-specific death increased 
with decline in BMI from roughly 25 kg/m2 and increased with increase in BMI from 25 
kg/m2• The increase in probability appeared to be higher for low BMI as opposed to high 
BMI. This effect might have been explained away by those patients with advanced stage 
breast cancer losing weight (BMI) due to their advanced disease. For this reason analysis 
was limited to early stage « stage III) breast cancer cases only (Figure 17). The 
nonlinear effect appeared to be remarkably similar in shape to Figure 16. The Wald test 
p-value assessing nonlinearity between BMI and breast cancer-specific death was p= 
0.01; indicating a significant nonlinear association between BMI and breast cancer-
specific death. 
4.3.6 Research Question 3: Testing Model Performance for the Model 
Predicting Breast Cancer-Specific Death 
As presented in Table 11, the bootstrap bias-corrected ROC AVC estimates assessing the 
difference in the nested model with and without BMhsplines were 0.8424 (bootstrap SE 
0.02; BC 95% CI= 0.81-0.87) and 0.8331 (bootstrap SE 0.02; BC 95% CI= 0.80-0.87). 
Although not statistically significant at the 0.05 level, the results are trending to 
significance (p= 0.08) and are suggestive of a possible difference in the ROC AVCs. A 
ROC AVC comparing the nested model with and without BMhsplines for breast cancer-
specific death is presented in Figure 18. 
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Figure 18. ROC Curve for Breast Cancer-Specific Death in the Nested Model with 
and without BMI3splines in the HFHS (Detroit, Michigan) Data 
The uncorrected and bootstrap optimism-corrected c-statistics predicting breast 
cancer-specific death were 0.842 and 0.824. The model predicting breast cancer-specific 
death demonstrated good discriminatory ability between those subjects who did not and 
did experience a death from breast cancer. The model predicting breast cancer-specific 
death had a Nagelkerke's pseudo R2 of 0.374 and a bootstrap optimism-corrected 
Nagelkerke's pseudo R2 of 0.327. Furthermore, the Hosmer-Lemeshow goodness-of-fit 
testp-value was 0.210, implying that the model's estimates fit the data at an acceptable 
level. 
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A calibration plot (plotting the predicted probabilities vs. observed probabilities) 
is presented in Figure 19. In assessing the calibration plot, the calibration slope of the 
breast cancer-specific death prognostic model is 0.892. Also, the mean absolute error 
(0.025) and 90th percentile absolute error (0.050) are relatively small. This indicates that 
the model predicting breast cancer-specific death is reasonably well calibrated as 
measured by the calibration slope, mean absolute error and 90th percentile absolute error. 
4.3.7 BMI3splines and Breast Cancer-Specific Death in Multivariate Cox 
Regression 
As depicted in Table 12, BMI3splines were highly associated with breast cancer-specific 
death (LRT p= 0.0003). The c-statistic for the model predicting breast cancer-specific 
death was c= 0.82. 
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CHAPTER 5: DISCUSSION & CONCLUSIONS 
5.1 Pertinent Study Findings 
5.1.1 The Association between BMI3spiines and Breast Cancer Outcomes 
Adjusted for age, stage, ERIPR status, surgery, radiation therapy and chemotherapy, 
BMhsplincs near or at breast cancer diagnosis were independently associated with breast 
cancer recurrence/progression and breast cancer-specific death (LRT p= 0.023 and LRT 
p= 0.010, respectively). 
5.1.2 The Nonlinear Relationship between BMI3spiines and Beast Cancer 
Outcomes 
The probability of breast cancer recurrence/progression and breast cancer-specific death 
increased with decline in BMI from roughly 25 kg/m2 and increased with increase in BMI 
from 25 kg/m2. A J-shaped relationship best described the relationship between BMI and 
breast cancer recurrence/progression and breast cancer-specific death. The Wald test p-
value assessing nonlinearity between BMI and breast cancer recurrence/progression and 
breast cancer-specific death were p= 0.02 and p= 0.01, respectively. This indicated a 
significant nonlinear relationship between BMI and breast cancer recurrence/progression 
and breast cancer-specific death. 
5.1.3 Breast Cancer Prediction Models 
The ROe Aves for breast cancer recurrence/progression and breast cancer-specific death 
were not statistically significant. However, results were trending to significance and were 
suggestive of a possible difference in the Roe Aves, in the nested model with and 
without BMhsplines (p= 0.14 and p= 0.08). The c-statistic demonstrated good 
discriminatory ability between those subjects who did not and did experience a breast 
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cancer recurrence/progression (uncorrected c-statistic= 0.801 and bootstrap optimism-
corrected c-statistic= 0.782) and those who did not and did die from breast cancer 
(uncorrected c-statistic= 0.842 and bootstrap optimism-corrected c-statistic= 0.824). The 
goodness-of-fit test implied that breast cancer recurrence/progression and breast cancer-
specific death estimates fit the data at an acceptable level (p= 0.210 and p= 0.699, 
respectively). In assessing calibration, the bootstrap optimism-corrected calibration 
slopes are relatively large for breast cancer recurrence/progression and breast cancer-
specific death (0.883 and 0.892) whereas the mean absolute errors (0.018 and 0.025) and 
90th percentile absolute errors (0.038 and 0.050) are relatively small for breast cancer 
recurrence/progression and breast cancer-specific death, respectively. As a result, models 
predicting breast cancer recurrence/progression and breast cancer-specific death are well 
calibrated. 
5.2 Past Study Findings 
5.2.1 Independent Relationship between Nonlinearly Modeled BMI and 
Breast Cancer Outcomes 
Our results demonstrated a nonlinear association between BMI3splines near or at breast 
cancer diagnosis and breast cancer recurrence/progression and breast cancer-specific 
death. Suissa and colleagues found a similar nonlinear association however BMI was 
modeled using quadratic terms. Also, BMI was nonlinearly associated with breast cancer 
recurrence and overall survival. 87 Then Suissa and colleagues' results were validated by 
Goodwin and colleagues.71 Similarly, Goodwin and colleagues demonstrated that BMI, 
modeled using quadratic terms, represented a significant improvement over the linear 
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mode1. Likewise, a significant association between BMI and distant recurrence and 
overall survival persisted.71 
As previously mentioned, quadratic terms are limited in that they can only 
describe a limited number of nonlinear patterns and estimates are unstable in extreme 
ranges such as the tails.89 However, this study modeled BMI using restricted cubic 
splines as this method is deemed superior89. That is because restricted cubic splines are 
able to describe a greater range of nonlinear patterns and thus fit the data better. 16, 88 
5.2.2 Describing the Nonlinear Relationship between BMI and Breast Cancer 
Outcomes 
Suissa and colleagues demonstrated that the probability of overall survival was concave 
and lowest at a BMI of 34 kg/m2 • 87 A BMI of 34-50 kg/m2 was associated with the 
highest probability of overall survival. However, the probability of overall survival was 
highest for high vs. low BMI.87 Furthermore, Goodwin and colleagues found a similar J-
shaped relationship and demonstrated that women with either low or high BMI « 20 
kg/m2 or >25 kg/m2) had the highest hazard of distant recurrence and overall surviva1.71 
Similar to Suissa and colleagues' work, the effect was highest for high vs.low BMI. 
Contrary to the risk picture demonstrated by Suissa and colleagues and Goodwin 
and colleagues 71,87, in this study, models with restricted cubic splines conveyed that the 
probability was highest for low vs. high BMI. Results from this study indicate and 
support a J-shaped·relationship between BMI and breast cancer recurrence/progression 
and breast cancer-specific death. It was postulated that this effect might have been 
explained away by those patients with advanced stage breast cancer losing weight (low 
BMI) due to their advanced disease. However, this explanation was not adequate because 
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when analysis was limited to early stage breast cancer cases only « stage III); the 
nonlinear effect appeared to be similar in shape. 
5.2.3 Low BMI and Breast Cancer Outcomes 
Studies also found an association between underweightness (low BMI) and breast cancer 
prognosis. Moon and colleagues found that adjusted for age, tumor size, lymph node 
metastasis, ERiPR status, grade and lymphovascular invasion underweight patients had a 
significantly lower overall survival and breast cancer-specific surviva1.61 Also, 
underweight women had a significantly higher risk of local recurrence and distant 
metastasis.61 In addition, Chen and colleagues concluded that low BMI and young age 
were poor prognostic factors for locoregional recurrence in multivariate analysis.98 
Similarly Marret and colleagues' work found that low BMI was an independent 
predictive factor oflocal recurrence after breast conserving therapy.99 To date, majority 
of studies have focused on the relationship between high BMI and breast cancer 
prognosis and ignored the impact oflow BMI and breast cancer prognosis. Failure to 
recognize such a subgroup may affect interpretations of previous study results. In 
addition, this study helped more accurately characterize the probability/risk of adverse 
outcomes in breast cancer patients- to a level not previously achieved. 
5.3 Study Limitations 
5.3.1 Study Power 
Study power was possibly an issue because it may have been low. If the sample size were 
larger than breast cancer models would have better prediction. To prevent overfit in 
prediction modeling, 10-20 outcomes per predictor are required in model development. 
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5.3.2 Misclassification Bias 
There may be more misclassification of time of recurrence/progression and less 
completeness of recurrence/progression data compared to death data. 
5.3.3 Missing Data 
The proportion of patients used in the breast cancer recurrence/progression and breast 
cancer-specific death models was 76.4% and 82.0%. Some of the covariates used in 
modeling such as surgery, radiation therapy, chemotherapy and BMI3spiines contained 
missing data. Patterns of missing values are reported in Appendix 2. Future analyses may 
consider using multiple imputation methods as simulation studies have demonstrated that 
imputing data can be superior compared to using complete case analysis. tOO 
5.3.4 BMI as a Proxy Measure for Obesity 
BMI is a proxy measure for obesity however BMI does not discriminate between body fat 
and lean body mass. A study conducted by Loi and colleagues demonstrated a high 
correlation between BM! and body fat (r= 0.91; p < 0.001).80 These findings were 
reported in an Asian population. Results might be different depending on the ethnic 
variation but for the most part in clinical practice and research, BMI is convenient and 
simple while demonstrating a high correlation with percent body fat. 79 
5.3.5 Absence of Genetic Mutation Data 
Models predicting breast cancer recurrence/progression and breast cancer-specific death 
did not include genetic mutation data. Beenken and colleagues reported that adjusted for 
age, stage, nodal status, grade and ERiPR status, p53 tumor suppressor gene mutation and 
c-erB-2 overexpression have independent prognostic significance with breast cancer 
recurrence and overall survival. tOt Overexpression of c-erB-2 and p53 tumor suppressor 
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gene mutation correlated strongly with poor patient survival. After a 16 year follow-up, 
Beenken and colleagues suggested that coexpression of c-erB-2 and p53 tumor 
suppressor gene mutation may have more prognostic significance than traditional 
prognostic factors such as stage and nodal status. IOI Similarly, Allred and colleagues 
suggested a prognostic role for p53 tumor suppressor gene mutation. 102 Likewise, Lai and 
colleagues found that adjusted for stage, treatment and number of mutations, patients 
with p53 tumor suppressor gene mutations had significantly greater breast cancer-specific 
deaths compared to patients without p53 tumor suppressor gene mutations.103 
Furthermore, the presence of a dose-response relationship between the number of 
mutations and the likelihood of dying from breast cancer provided evidence of a causal 
relationship between p53 tumor suppressor gene mutations and breast cancer disease-free 
survival. 103 Mechanistically, it has been postulated that breast cancers co~expressing c-
erB-2 and p53 tumor suppressor gene mutations have lost a key mechanism for control of 
cell proliferation and have gained an activator of malignant cell potential, resulting in a 
highly malignant tumor phenotype. 10lAccording to the literature future prognostic models 
need to combine the predictive power of individual molecular biomarkers with specific 
clinical and pathologic factors. 
The HFHS comorbidity dataset did not contain-acquired mutation data however 
germline mutation data such as family history was available and is considered a surrogate 
measure for an inherited genetic component. Since minimal genetic data was available 
this study did notincorporate a genetic aspect. Family history was assessed in unadjusted 
and multivariate logistic regression for breast cancerrecurrence/progression and breast 
cancer-specific death. In unadjusted logistic regression family history was not 
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significantly associated with breast cancer recurrence/progression (OR= 1.03; 95% CI= 
0.72-1.48; p= 0.87). In multivariate analysis adjusted for age, stage, ERiPR status, 
surgery, radiation therapy, chemotherapy and BMI3splines, family history remained 
insignificant (OR= 1.19; 95% CI= 0.75-1.88; p= 0.46). Similarly, family history was not 
significantly associated with breast cancer-specific death in unadjusted and multivariate 
analysis, adjusted for age, stage, ERiPR status, surgery, radiation therapy, chemotherapy 
and BMI3splines, (OR= 1.20; 95% CI= 0.80-1.79;p= 0.38 and OR= 1.38; 95% CI= 0.83-
2.30; p= 0.22, respectively). As a result, adding family history to the association study 
would be irrelevant because family history was not significantly associated with breast 
cancer outcomes. Furthermore, by definition, a confounder must be associated with the 
exposure under study. To date, we are unaware of evidence indicating associations 
between p53 and c-erB-2 and BMI. On the other hand, incorporating tumour-specific 
genetic data to the prediction study might be relevant and results mayor may not be 
affected because to improve prediction very strong effect estimates (high ORs) are 
needed. 
5.4 Study Strengths 
5.4.1 Study Design 
The strength of this study was the study design utilized. The historical cohort design is 
valid because exposure data is collected before the outcome occurs therefore there is no 
recall bias. Also, because it is a cohort, with naturally occurring exposures and outcomes, 
it is not vulnerable to selection bias the way a case-control study would have been. 
Furthermore, the historical cohort design is convenient because a preexisting cohort of 
incident breast cancer cases is used to collect exposure data (BMI) and the outcomes 
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(breast cancer recurrence/progression and breast cancer-specific death) are ascertained at 
the time the study is initiated. For this reason, results are collected sooner because the 
study has begun with a preexisting cohort to reduce the duration of the study. 
5.4.2 Analytic Approaches 
Using restricted cubic splines as an approach to studying nonlinear effects between BMI 
and breast cancer recurrence/progression and breast cancer-specific death strengthened 
the results of this study. 
5.4.3 Discrimination, Calibration and Validation 
Sophisticated statistical techniques such as discrimination and calibration were utilized to 
assess breast cancer prognostic models. Furthermore, results were internally validated 
using bootstrapping. Empirical and simulation studies indicate that bootstrapping internal 
validation is more efficient and potentially encompasses less bias than using the cross-
validation approaches, where the sample is split into model development and testing 
subsets. 16, 88 To date, research has not implemented sophisticated statistical modeling 
techniques such as discrimination and calibration to adequately assess the predictive 
ability of breast cancer recurrence/progression and breast cancer-specific death models. 
5.4.4 Completeness of Cause-of-Death Data 
Survival follow-up and cause-of-death data were collected from SEER tumor registries 
and death certificates which are generally thought to be an accurate source of data 
collection since the exact date of death is specified. In comparing death certificates to 
hospital and autopsy records, death certificates are deemed as a more valid source for 
mortality data. As well, the US is required by law to have a death registry therefore the 
data are known to be complete. 104 
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5.4.5 Inclusion of Early and Late Stage Breast Cancer Patients 
Previous studies only took early stage breast cancer cases into account. This study 
included early and late stage breast cancer cases. 
5.5 Biological Plausibility 
5.5.1 Biological Explanations for Low BMI 
Possible biological rationales that may explain the risk picture observed in this study and 
that past studies reported have been suggested for low and high BMI. The mechanisms 
between BMI and breast cancer prognosis are complex and are probably different for low 
and high BMI. However, there have been several biological rationales explaining the 
impact of low BMI on local recurrence but these hypotheses are not well established.98, 99 
Timing of weight gain is considered a breast cancer risk factor. Women who 
progressively gain weight from puberty to menopause are considered to be at risk for 
developing breast cancer. 105 Another possible explanation is high endogenous estrogen 
levels observed in premenopausal lean women. Premenopausal lean women have higher 
estradiol levels compared to overweight women, while BMI is positively related to 
estradiol in postmenopausal women.98 
Moon and colleagues suggest additional mechanisms that explain the association 
between low BMI and breast cancer prognosiS.61 One such explanation is the interaction 
between tumor cells and circulating immune cells through various molecular signals, 
from initial carcinogenesis to metastasis.61 Immune cells may inhibit or promote tumor 
progression and influence the efficacy of systemic antitumor treatments. In addition, 
patients showing severe-undernutrition and micronutrient deficiency, cytokinereactions 
and subsequent activation of the immune system are compromised, affecting tumor-
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immune system interactions. As a result, this may be associated with an increased risk of 
breast cancer recurrence.61 Finally, another possible mechanism linking underweightness 
and increased risk of breast cancer recurrence are the tumor-modulating roles of local 
systemic adipocytes. 61 Animal experiments demonstrate that the presence of mammary 
adipocytes is critical for mammary gland development and irradiation of mammary fat 
pads causes malignant progression of normal mammary cells; suggesting a protective role 
for mammary adipocytes.61 
5.5.2 Biological Explanations for High BMI 
The biological rationale explaining high BMI is clearer and more established. The 
biological effect of obesity on prognosis is associated with excessive endogenous 
estrogen production. This effect is strongest in those women who are postmenopausal. In 
premenopausal women, estrogen levels influenced by peripheral·aromatization in adipose 
tissue would be presumably not significant compared with that produced by functioning 
ovaries. Even after covariate adjustment, obesity remained to be a significant predictor of 
breast cancer recurrence and all cause mortality on both ERiPR tumors; suggesting other 
biological influences aside from estrogen may be responsible for this effect. 80 
In obese premenopausal women, the hormonal make-up is different and obesity is 
associated withhyperandrogenism, hyperinsulinemia and lower serum-binding hormone 
globulin.80 For example, hyperinsulinemia can be a potential mediator of the adverse 
effect of obesity in premenopausal breast cancer patients.8o As a result, there is biologic 
rationale for an adverse prognostic effect of insulin.71 Approximately, 90% of breast 
cancer cells express IGF-l, IGF-2, insulin and hybrid insulinlIGF-l receptors. IGF-l and 
insulin receptors, mediate the mitogenic effects of insulin, are frequently overexpressed 
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in breast cancer patients, with levels of insulin receptor that are 6-10-fold higher than in 
normal breast epithelium.71 
5.6 Clinical and Public Health Implications 
In research, hypothesis testing or causal modeling is important because if significant 
results are reported it enables the researcher to further investigate the etiology and 
mechanisms of action that might be driving the association. Therefore, it allows the 
researcher to determine the underlying cause that is affecting the exposure/disease 
relationship. If direct causal mechanisms are identified, randomized clinical trials are 
needed to see if dietary programs and exercise interventions or both may reduce elevated 
BMI and increase low BMI in order to improve breast cancer outcomes. 
Prognostic models are crucial in clinical settings because physicians and health 
policy makers are required to make predictions on patient survival. Physicians use 
prediction models in their decision-making on screening and treatment of disease in high 
risk groups, diagnostic work-up (i.e. ordering a risky or expensive test) and choice of 
therapy. Clinical prediction models have the potential to provide the evidence-based input 
for shared decision-making, by providing estimates of the individual probabilities/risks. 16 
Additionally, prognostic models are utilized by public health officials to assess disease 
burden. The health care system utilize prediction models to determine how much a 
patient is costing the health care system, as well as, help to develop plans to address 
patient needs. 16 
5.7 Future Research 
First, BMI, which attempts to capture adiposity, is weighted to the square of height and 
this leads to low height individuals having adiposity overestimated in many individuals. 
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As a result, future studies may want to consider dissecting the findings by strata of 
height. 
Second, study results are in need of external validation using independent study 
samples in order to validate the study results presented in this study. In addition, once 
findings are externally validated, superior models need to be built incorporating BMI but 
also additional markers excluded from our study because of absence of data, i.e. genetic 
tumor markers and functional status need to be included in future breast cancer 
prognostic models. 
Finally, to implement breast cancer prediction models in clinical practice future 
studies need to construct nomograms for breast cancer recurrence/progression and breast 
cancer-specific death. These nomograms can be utilized by physicians and patients to 
generate predictions for patient survival. A nomogram predicting breast cancer 
recurrence/progression and breast cancer-specific death and directions on filling out the 
nomogram is presented in Appendix 3. 
5.8 Conclusions 
The results of this study indicate that adjusted for all prognostic covariates, BMI3spiines 
near or at breast cancer diagnosis were independently associated with breast cancer-
specific death. According to the Wald test for nonlinearity, BMI was nonlinearly 
associated with breast cancer-specific death. A l-shaped relationship best described the 
association between BMI and breast cancer-specific death. In addition, the probability of 
death due to breast cancer was highest for low vs. high BMI. 
Discrimination as measured by ROC AVe, although not statistically significant 
but trending to significance was suggestive of a possible difference in the ROe Aves, 
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between the nested model with and without BMI3splines. Furthermore, the Hosmer-
Lemeshow goodness-of-fit test demonstrated that the breast cancer-specific death 
estimates fit the data at an acceptable level. Finally, the model including BMI3splines to 
predict breast cancer-specific death was well calibrated as measured by the calibration 
slope, mean absolute error and 90th percentile absolute error. 
Overall, this new knowledge may aid in the revision of pre-existing nutritional 
and exercise programs or may help in the development of new interventions that are 
specifically geared towards women diagnosed with breast cancer. In women with a low 
BMI and who are diagnosed with breast cancer, nutritional programs that are specifically 
designed to increase nutritional intake, for example through increasing caloric intake, in 
order to increase BMI may be implemented. On the other hand, in women with a high 
BMI and who are diagnosed with breast cancer, nutritional programs that lower 
nutritional intake may be implemented to lower BM!. Greater emphasis should be placed 
on those prognostic factors that are modifiable such as BMI in order to increase survival 
or improve prognosis. 
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Figure 1.1- Graphical Test of Proportional Hazards Assumption between Stage II 
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Figure 1.2- Graphical Test of Proportional Hazards Assumption between Stage III 
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Figure 1.3- Graphical Test of Proportional Hazards Assumption between Stage IV 
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Figure 1.4- Graphical Test of Proportional Hazards Assumption between Stage 
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Figure 1.6- Graphical Test of Proportional Hazards Assumption between ERIPR 
Unknown and Breast Cancer-Specific Death 
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Figure 1.9- Graphical Test of Proportional Hazards Assumption between 
Chemotherapy and Breast Cancer-Specific Death 
Table 1.1- Test of Proportional Hazards Assumption for Model Predicting Breast 
Cancer-Specific Death 
Ti me : Rank ( t ) 
rho chi2 df Prob>chi2 
------------+---------------------------------------------------
age10FIN 0.04777 0.39 1 0.5329 
stagedv2 0.05810 0.51 1 0.4769 
stagedv3 0.02024 0.07 1 0.7964 
stagedv4 -0.07410 0.99 1 0.3205 
stagedvun 0.02293 0.07 1 0.7869 
IERPRtri 1 0.32676 17.90 1 0.00--00 
IERPRtri 3 0.02301 0.08 1 0.7789 
surg -0.05643 0.63 1 0.4288 
radi 0.06198 0.60 1 0.4390 
chern 0.17511 5.64 1 0.0176 
BMI4k3sp1 -0.14671 4.03 1 0.0448 
BMI4k3sp2 0.15921 4.35 1 0.0370 
BMI4k3sp3 -0.15529 4.00 1 0.0454 
------------+---------------------------------------------------
global test I 31. 22 13 0.0031 
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Appendix 2- Missing Value Patterns 
Variable I type obs rnv variable label 
-------------+-----------------------------------
BRCArecprog2 float 799 98 Recurrence/progression 
expireBRCA float 897 0 Breast cancer death 
age10FIN double 897 0 
stagedv2 float 897 0 
stagedv3 float 897 0 
stagedv4 float 897 0 
stagedvun float 897 0 
IERPRtri 1 byte 897 0 ER/PR positive 
IERPRtri 3 byte 897 0 ER/PR negative 
surg byte 858 39 
radi byte 819 78 
chern byte 811 86 
BMI4k3sp1 float 816 81 
BMI4k3sp2 float 816 81 
BMI4k3sp3 float 816 81 
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Appendix 3- Nomogram 
Points 
ag:e1 
stag en ewM Rf 
ERPRtri 
surg 
radi 
ch:em 
bmi 
Total Points 
Linear Predictor 
Nomogram Predicting Breast Cancer Recurrence/Progression 
o 10 2:v 30 4.0 50 60 70 
!JJ3P,,!IIJIJ]4 
2 4 6 B 
fi 
1 
i..,---J 
3 0 
1 
~ 
~ 
u 
fi 
, Ij ¥ 
30 
II 
o 
5lE:540 20 '1 5 
o 10 2'0 3D 4D 5{j 60 70 
-3 -2 
Prubabiltty of Breast Cancer Recurrence/Progression 
so 00 
:1 
2 
so :Hl 100 
-1 n 
O,OS ill S 1125 0.35 0.4 &D.55 0,6<5 
111 
100 
.:4 
110 
Nomogram Predicting Breast Cancer-Specific Death 
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Directions: To obtain the nomogram predicted probability, locate the patient values at the age, stage, ERiPR status, treatment 
(surgery, radiation therapy and chemotherapy) and BMI axes. Then, draw a vertical line to the "points" axis to determine how 
many points are attributed for each variable value. Sum the points for all the variables described above. Locate the sum on the 
"total points" line and draw a vertical line to the appropriate probability scale, to obtain the predicted probability for the breas 
cancer outcomes. 
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